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I. ABSTRACT  
African horse sickness is one of the most deadly infectious diseases of horses. The 
disease is caused by African horse sickness virus (AHSV), an arbovirus transmitted by 
culicoides midges. AHSV is classified within the genus Orbivirus, family Reovirdae. 
The AHSV genome is composed by ten segments of double stranded RNA (dsRNA) 
encoding seven structural and at least four non-structural (NS) proteins.  
AHSV shares structural and functional similarities with Bluetongue virus, the 
‘prototype’ species of the genus Orbivirus. An alternative open reading frame (ORF), 
overlapping the main ORF encoding the VP6, has been identified in segment 9 in 
both AHSV and BTV. This additional ORF encodes the non-structural protein NS4. The 
BTV NS4 localises in the nucleoli of the infected cells. NS4 is an interferon antagonist 
and a determinant of virus virulence.  
In this thesis, I aimed to characterise the AHSV NS4. Unlike the BTV NS4, the AHSV 
NS4 are relatively variable mong different virus strains. I have divided these proteins 
into four different subtypes: NS4I, NS4-IIα, -IIβ, and IIγ based upon their sequence 
similarity and on the presence of N-terminal or C-terminal truncations. In contrast 
to BTV, all four of these NS4 types localise in the cytoplasm of either transfected or 
infected cells. In addition, in transient transfection assays all the NS4 types show 
the ability to hamper gene expression, with NS4-IIβ being the most efficient. 
In order to further understand the biological significance of the AHSV NS4 we used 
reverse genetics to generate viruses expressing the four types of NS4 (AHSV-NS4-I, 
AHSV-NS4-IIα, AHSV-NS4-IIβ, AHSV-NS4-IIγ) and the corresponding NS4 deletion 
mutants (AHSV-ΔNS4-I etc.). 
Deletion of NS4 did not affect virus replication kinetics in either KC cells or 
interferon incompetent cells such as the BSR cell line. Similarly, both AHSV-NS4-IIβ 
and the corresponding ΔNS4 mutant showed similar replication kinetics in the 
interferon competent E. Derm cell line and in primary horse endothelial cells. In 
contrast, AHSV-NS4-I, AHSV-NS4-IIα, and AHSV-NS4-IIγ replicated more efficiently 
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than the corresponding ΔNS4 viruses in these horse cells. Interestingly, the defects 
in replication of the NS4 viruses were removed after treatment with an inhibitor of 
the JAK/STAT pathway. Indeed, we observed that primary horse cells infected with 
the NS4 mutants released higher levels of type I interferon (IFN) than cells infected 
with the corresponding NS4 expressing viruses. In addition, we found the NS4 to be 
a determinant of virus virulence in vivo in NIH-Swiss mice infected with the viruses 
described above.  
Collectively, the data described in this thesis suggest that the NS4 is one of the 
proteins used by AHSV to modulate the IFN response.  
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 Literature review 
This review of the literature will cover initially the historical outbreaks, 
epidemiology, and the different clinical manifestations of African horse sickness 
virus (AHSV) infection. This information highlights the importance of the disease and 
why studies such as the one presented in this thesis, which investigate the role of 
viral proteins in modulating the host immune response, are important. In addition, 
an introduction into the concepts of viral virulence and how the virus interacts with 
the host innate immune response will be also given. In several instances, due to the 
relatively little information available directly on AHSV, parallels have been based 
on bluetongue virus (BTV), the prototype member of the Orbivirus genus.  
1.1 African horse sickness 
African horse sickness (AHS) is one of the most devastating infectious diseases of 
equids. The mortality rates vary between different equid species affected by the 
disease. In horse, the mortality rate can be up to 95%, whereas in zebra, there are 
no significant clinical signs when infected (Awad, Amin et al. 1981). The causative 
agent of the disease is African horse sickness virus (AHSV). The virus is non-
contagious and infection is spread between the mammalian hosts by insect vectors. 
AHS is mainly transmitted by Culicoides spps biting midges, with Culicoides imicola 
(C. imicola) being the main insect host. Similarly to BTV, other Culicoides spp are 
capable of transmission including, C.bolitinus (Du Toit 1944, Mellor 1993, Wellby, 
Baylis et al. 1996). Other insect vectors trapped in the field have been found to be 
infected with AHSV and include occasionally Aedes, Culex and Anopheles 
mosquitoes, Hyalomma and Rhipicephalus ticks and sandflies (Ozawa and Nakata 
1965, Ozawa, Shad-Del et al. 1970, Mellor, Boned et al. 1990, Mellor 1993, Mellor 
2000). AHSV has a greater capacity to infect a range of different insect vectors in 
comparison to BTV which to date only infects Culicoides spps. To date, 9 serotypes 
of AHSV have been identified in field (Howell 1962).  
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1.1.1 Historical outbreaks and epidemiology of African horse sickness 
Traditionally, AHS disease was endemic in the sub-Sahara area, especially in the 
tropical and sub-tropical areas, spreading to South Africa (Mellor and Boorman 
1995). African horse sickness is an ancient disease. As early as in 1327, a disease 
resembling AHS was reported in Yemen and over 200 years later, in 1569, there was 
a documented report in East Africa of horses becoming affected by AHS after they 
were imported from India (MacLachlan and Guthrie 2010). In southern Africa, this 
disease was first recognised in 1657 when the horses were initially introduced in the 
region. 
The first major breakout of AHS occurred in 1791, and during that breakout over 
1,700 horses were killed due to the pathology associated with AHSV (Mellor and 
Boorman 1995). In the subsequent following centuries, there have been more than 
10 major outbreaks that have swept through Africa and southern Europe. The largest 
recorded breakout occurred in South Africa between 1854 and 1855 when 70,000 
animals died, accounting for 40% of the local population (Guthrie, Quan et al. 2009). 
The outbreak of AHS in 1959–60 was the largest documented in recent times 
spreading throughout the Middle East and as far west as South-West Asia with death 
of more than 300,000 equids (Anwar and Qureshi 1972). In recent times, there have 
been more recorded outbreaks and several cases indicating that AHS spread from 
Africa into southern Europe around the Mediterranean basin. In 1965, AHS was first 
reported in Morocco before spreading throughout Algeria and Tunisia and crossing 
into Spain via the Strait of Gibraltar in 1966 (Lubroth 1992). 
The second incursion of AHSV into Europe occurred in 1987, when infected animals 
were imported into Spain. Although an extensive vaccination program was 
undertaken, the virus spread into southern Spain and arrived in Portugal in 1989. 
The last clinical cases were reported in 1990 (Zientara, Sailleau et al. 1998). There 
have been outbreaks occurring north of the Sahara, the natural barrier of AHSV 
spread with reported outbreaks in Ethiopia in 2003 and 2008 (Aklilu, Batten et al. 
2014). These two outbreaks killed more than 2,000 of horses. In 2007, the disease 
was reported in Nigeria, Senegal and Gambia in the west of Africa indicating the 
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virus had moved from the southern Africa into both the east and west of Africa with 
a greater frequency of outbreaks (Diouf, Etter et al. 2013, Fall, Fall et al. 2015).  
To date, AHS breaks out frequently and severely in southern Africa. The Sahara 
Desert, to date, has proved to be an effective barrier that prevented the disease to 
spread geographically. However, with the human activities and global climate 
changing, AHS started to extend to Northern Africa and other places of the world 
(Baylis, Mellor et al. 1999, Harvell, Mitchell et al. 2002), including countries 
surrounding the Mediterranean (Spain and Portugal) (Rodriguez, Hooghuis et al. 
1992, Portas, Boinas et al. 1999), Arabian Peninsula (Wilson, Mellor et al. 2009), and 
South Asian subcontinent including India and Pakistan (Mellor 1993). Although, not 
as successful as BTV, which is now endemic in Europe after spreading from southern 
Africa, the similarities in the rate and types of incursion routes are high. 
1.1.2 Host range of African horse sickness 
Equids are the susceptible species of AHS, including horses, mules, donkeys and 
zebras. Horses are the most susceptible species and infection with AHSV general 
results in the development of acute and subacute forms of the disease with very 
high mortality rates. Donkeys and mules, in comparison develop an infection that is 
often subclinical and resolves while infection in zebras is asymptomatic. Zebras are 
postulated to be the main reservoir of AHSV in the wild as their habitat and the 
epidemic area of the disease overlap (Baylis, Mellor et al. 1999). It is believed that 
zebras also play an important role in allowing virus persistence in the sub-Sahara 
area. Virus and/or viral antibodies have been detected in other species, including 
camels, elephants and rhinoceroses (Moustafa and El-Bakry 1984, Barnard, Bengis et 
al. 1995, Van Vuuren and Penzhorn 2015), however their biological role in allowing 
epidemics and transmission is insignificant. Dogs are reported to develop a very 
severe and short clinical disease, which is fatal, due to the ingestion of the 
contaminated horse meat indicating that the dog may be another susceptible 
species. Traditionally, it was hypothesised that dogs may not play a role in disease 
transmission (Binepal, Wariru et al. 1992, Alexander, Kat et al. 1995), but a recent 
report has shown the direct transmission of AHSV to dogs without ingesting 
contaminated meat (Van Sittert, Drew et al. 2013). 
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1.1.3 Clinical signs of African horse sickness 
The nature of disease and the outcomes of infection are often dependent on several 
factors that are determined by the host-virus interplay including virus strain, breed 
etc. (Howell 1963, Burrage and Laegreid 1994). The incubation period prior to the 
onset of disease varies from 3 to 15 days depending on the virus and the host. Unlike 
BTV or Epizootic haemorrhagic disease virus (EHDV), which have a similar clinical 
outcome that has a sliding scale of severity, AHSV infection results in several 
clinically different outcomes. The 4 principal manifestations of AHS, in order of 
increasing severity are horse sickness fever, cardiac form, mixed form and a 
pulmonary form. There are not known viral determinants or host-associated factors 
that determine the severity of the clinical manifestations. It is reported that the 
mixed form is the most frequently occurring clinical outcome (reviewed by (Zientara 
and Lecollinet 2015)). However, a retrospective study on data from the 2009–2010 
outbreak in Ethiopia reported all forms of the disease with cardiac the most 
prevalent form (54.8%), followed by horse sickness fever, pulmonary (7.1%) and 2.4% 
with the mixed form (Aklilu, Batten et al. 2014). This highlights the differences in 
the reporting of prevalence of the clinical manifestation. 
Horse sickness fever is the mild form and generally not lethal. Infection results in a 
mild to moderate increase in body temperature between 40–40.5 ℃ and general 
malaise for 1 or 2 days. This form is frequently observed in partially immune 
(vaccinated) horses or in response to the live attenuated strains such as the vaccine 
in the susceptible equid species (horse) or in donkeys or zebras (Mellor and Hamblin 
2004, Zientara and Lecollinet 2015). In the cardiac form, which is sometimes 
referred to as the subacute form, clinical signs usually appear 7 to 12 days p.i and 
is characterised by high body temperature lasting for weeks (Mellor and Hamblin 
2004, Zientara and Lecollinet 2015). The cardiac form of AHSV infection results in a 
swollen head and neck due to oedema, which is particularly noticeable around the 
supra-orbital fossa region of the eye. Conjunctivitis, abdominal pain and shortening 
of breath/laboured breathing are also common clinical signs of this form. The 
mortality rate ranges between 50% and 70% with surviving animals recovering within 
7 days (Howell 1963, Mellor and Hamblin 2004, Zientara and Lecollinet 2015). 
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The pulmonary form is the most severe and has the highest case fatality rate: up to 
95% of infected horses will die 7 days p.i. (Mellor and Hamblin 2004). The onset of 
disease is very rapid and it is common for horses to die without displaying any 
previous signs of disease. Clinical signs include depression, increased body 
temperature (39–41℃), and followed by respiratory distress and severe dyspnoea. 
Spasmodic coughing and severe sweating occurs and at the terminal stage frothy 
fluid oozes out of the nostrils. The mixed form of disease is reported as the most 
common clinical outcome to AHSV infection of horses. It is a combination of the 
pulmonary and cardiac form with mortality rates around 70%. Death occurs 3–6 days 
after the onset of fever (Howell 1963, Mellor and Hamblin 2004, Kazeem, Rufai et 
al. 2008, Van Sittert, Drew et al. 2013, Zientara and Lecollinet 2015) 
1.1.4 Vaccine of African horse sickness 
As clinical signs of AHS develops very fast and causes badly tissue damage and highly 
death rate, one of the most important methods for the disease control and 
prevention is vaccination.  
To date, the only commercially available vaccines are polyvalent attenuated 
vaccines from Onderstepoort Biological Products (OPB) in South (Mellor and Hamblin 
2004). The vaccines are first attenuated by multiple inoculating in mouse brain, and 
then are further attenuated through passage in cell culture. These vaccines are used 
in southern Africa currently and formulated into two vials which contains AHSV-1, -
3 and -4, and AHSV-2. -6, -7, and -8 respectively. It is recommended that the two 
vials of the vaccines should be administrated separately for at least three weeks, 
but no more than four weeks annually in late winter or early summer (von Teichman, 
Dungu et al. 2010). AHSV-9 is not included as this serotype has strong cross 
protection with AHSV-6(von Teichman, Dungu et al. 2010) and AHSV-9 is rarely 
epidemic in southern Africa historically (Mellor and Hamblin 2004). AHSV-5 is not 
included as well, because it is difficult to get attenuated strains and severe reactions 
and death have been reported after vaccination (Molini, Marucchella et al. 2015).  
A monovalent attenuated AHSV-9 vaccine that produced by National Laboratory of 
Senegal is widely used in West Africa where this serotype is widely epidemic and 
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causes serious outbreaks (Oura, Ivens et al. 2011). Whereas in Europe, an attenuated 
AHSV-4 monovalent vaccine which was produced by OPB was used also used in Spain 
and Portugal during 1987 to 1990 when AHSV-4 broke out in these areas (Portas, 
Boinas et al. 1999) as this is the only serotype that breakouts in Europe histrocally. 
Although, the live attenuated vaccines successfully help to control the endemic of 
AHSV, the commercial vaccines are still not licenced to use in the EU. There are still 
concerns for these vaccines usage. The vaccines are generated in South Africa, and 
using the vaccines world widely would introduce the viruses into other ecosystems. 
Furthermore, the attenuated virus genome could potentially reassort with field virus 
strain genome and generate the reassortant virus (von Teichman and Smit 2008). 
The virulence reversion and further reassortment are not able to control in field, 
which may cause potential risk. 
Inactivated vaccines are also developed. However, due to the difficulty of ensure 
complete inactivation of the vaccine and the expensive price, this vaccine is 
withdrawn from the market after AHSV annihilation from Europe (Mellor and Hamblin 
2004). 
Recently, a new AHSV antigen delivery system using modified vaccinia Ankara (MVA) 
has been described (Calvo-Pinilla, de la Poza et al. 2014). The MVA replication in 
mammalian cells delivers the AHSV VP2 as a foreign antigen and induces the host 
cellular and humoral immune responses to generate neutralisation antibodies. 
1.2 African horse sickness virus 
1.2.1 AHSV is a member of the Reoviridae 
The Reoviridae is the largest and most diverse family of dsRNA viruses and are 
classified as a Group III virus by the International Committee on Taxonomy of Viruses 
(ICTV). The virions have icosahedral symmetry but may appear spherical in shape 
and have a segmented genome consisting of 10 to 12 segments (Mertens 2004). 
Fifteen distinct genera have been identified within Reoviridae including the genus 
Orbivirus. This genus is the largest one, which consists of over 35 species including 
BTV, AHSV, EHDV and Equine encephalosis virus (EEV).  
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The name Orbivirus derives from the Latin world ‘orbis’, which means ring or circle, 
referring to the structure at core particles (see section 1.2.5 for description). The 
structural morphology is similar among different orbiviruses. The genome of 
orbiviruses is composed of 10 linear dsRNA segments. Although, the structure overall 
and virus activities are conserved among members of this genus, there is very little 
genetic similarity within and among genera of the Reoviridae.  
1.2.2 The AHSV genome 
The ~19.5 kb AHSV genome is composed of 10 dsRNA segments (Bremer, Huismans 
et al. 1990, Potgieter, Steele et al. 2002). The size of each segment varies from 
3,965 bp (segment 1) to 765 bp (segment 10) and the segments are named segment 
1 (largest) to segment 10 (smallest) based on gel migration (Gumm and Newman 
1982, Mertens, Burroughs et al. 1987, Bremer, Huismans et al. 1990). The profile of 
AHSV genome is similar but distinct from that of BTV or EHDV (Figure 1.1). Each 
AHSV segment contains 5’ and 3’ untranslated regions (UTRs) at both sides of the 
ORF. The length of the UTRs is variable. At 5’ end, the length of the UTR ranges 
from 12 bp (segment 2) to 25 bp (segment 5), while at the 3’ end range from 29 bp 
(segment 6) to 100 bp (segment 7). The sequences of UTRs of each segment show 
reverse complementarity, which suggests that secondary structures of the mRNAs 
that are transcribed could be formed (Roy 1989). The six terminal nucleotides are 
conserved and present on the 5’ and 3’ end of each segment of the AHSV genome 
(Roy 1989, Potgieter, Steele et al. 2002). The consensus sequence of this 
hexanucleotide sequence is found on all genome segments and is unique for each 
member e.g.,AHSV (5′-GUU(A/U)A(A/U)……AC(A/U)UAC-3) and BTV (5′-
GUUAAA…..(A/G)CUUAC-3′). This may be important for viral packaging (Burkhardt, 
Sung et al. 2014) and specific translation of viral proteins in the infected host 
(Wilkie, Dickson et al. 2003, Boyce, Celma et al. 2012). 
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Figure 1.1 Migration pattern of the dsRNA genome of different orbiviruses. Native acrylamide 
gel of dsRNA segments of BTV-10, EHDV-I and AHSV-4 (Roy, Mertens et al. 1994). The orbivirus 
genome is composed of 10 distinct dsRNA segments that can be separated by size. However, 
the size of the genome segments differs among different genera. Reproduced with permission. 
The segments are mostly monocistronic, although second functional, in-frame 
initiation codons or additional protein-coding ORFs have been identified in the AHSV 
genome as well as in BTV. The non-structural protein 4 (NS4) was initially identified 
by bioinformatics analysis in several different orbiviruses (BTV, GIV, etc.) and its 
expression has been confirmed in AHSV infected samples (Firth 2008, Belhouchet, 
Jaafar et al. 2011, Ratinier, Caporale et al. 2011, Zwart, Potgieter et al. 2015). 
Furthermore, another alternate ORF was identified in segment 10 of AHSV and BTV 
(Stewart, Hardy et al. 2015), as well as encoding proteins from alternate frames, 
the main ORFs in segment 9 and 10, NS3 and VP6, can be expressed from an in-frame 
AUG downstream of the initiating AUG forming NS3a and VP6a maybe due to leaky 
scanning (Hyatt, Zhao et al. 1993, van Niekerk, Smit et al. 2001). 
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1.2.3 AHSV virion 
AHSV is non-enveloped double-layered icosahedron virus of ~80 nm in diameter 
(Bremer 1976, Roy, Mertens et al. 1994, Manole, Laurinmäki et al. 2012) (Figure 
1.2). The virion is composed of 7 structural proteins (VP1 to VP7) (Bremer 1976, 
Burroughs, O'Hara et al. 1994, Burroughs, Grimes et al. 1995, Manole, Laurinmäki et 
al. 2012) similar to BTV (Hewat, Booth et al. 1992, Grimes, Jakana et al. 1997, 
Grimes, Burroughs et al. 1998, Zhang, Boyce et al. 2010). Some have reported the 
structure as a triple-layered particle but the subcore, consisting of the structural 
protein VP3, is highly fragile and for BTV has been shown to rapidly ‘fall’ apart (Kar, 
Ghosh et al. 2004). The cryoEM structure of AHSV has recently been solved (Manole, 
Laurinmäki et al. 2012).  
 
Figure 1.2 Schematic cartoon of the structure of the AHSV particle. The outer layer of AHSV is 
composed of the VP2 and VP5 proteins. The core of the particle packages the viral dsRNA 
genomic segments and the minor structural proteins VP1, VP4 and VP6. The layer of the core is 
formed by the VP3 and VP7 proteins. VP3 forms the scaffold of the layer on which VP7 is 
arranged and interacts with the outer layer (Mertens and Diprose 2004). Reproduced with 
permission. 
Three-D reconstruction of the AHSV virion, highlighted the structural similarities 
with BTV particularly within the core (VP3, VP7 inner capsid) (Manole, Laurinmäki 
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et al. 2012). The only striking difference is in the central region of the triskelion VP2 
outer capsid (Nason, Rothagel et al. 2004, Manole, Laurinmäki et al. 2012). The inner 
core (subcore) consists of 120 VP3 (~103 kDa) molecules in a T=1 arrangement, that 
is coated by 780 molecules (or 260 trimers) of VP7 (~38 kDa) arranged in a T=13 
pattern. Five trimers of VP7 form an asymmetric unit (Manole, Laurinmäki et al. 
2012) and each of the trimers in this unit is labelled (P, Q, R, S and T) based on the 
BTV nomenclature (Manole, Laurinmäki et al. 2012) (Grimes, Burroughs et al. 1998) 
(Figure 1.3). These asymmetric VP7 units form rings of pentamers and hexamers 
around the particle. AHSV VP7 has been shown to from sheets which consist solely 
of the 6-ringed formation (Burroughs, Grimes et al. 1995). 
 
Figure 1.3 The structure of the core particle of BTV. A. VP7 assembles the outer surface of the 
core. B. VP3 forms the inner surface (Grimes, Burroughs et al. 1998). Reproduced with 
permission. 
The AHSV inner capsid shell (~72 nm) is also called the core particle and packages 
the AHSV dsRNA genome complexed with the minor structural/enzymatic proteins 
(VP1, ~140 kDa; VP4 ~72 kDa; and VP6, ~36 kDa). Each viral particle contains 12, 24 
and 72 copies of VP1, VP4 and VP6 respectively (Van Dijk 1982). Each copy of VP1 
associates with a dimer of VP4 and hexamer of VP6 to form 12 transcription 
complexe units which are located at the 5-fold axes of the inner surface of core 
capsid (Grimes, Burroughs et al. 1998, Gouet, Diprose et al. 1999, Manole, 
Laurinmäki et al. 2012)  
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VP2 and VP5 form the outer capsid of the virion including 180 copies of VP2 and 360 
copies of VP5 molecules forming a T=13 lattice (Fig 1.3a). VP2 and VP5 together 
form a continuous layer and cover the viral core particle (Hewat, Booth et al. 1992, 
Manole, Laurinmäki et al. 2012) (Figure 1.4). VP2 molecules form triskelion trimers 
that site on the 260 VP7 trimers. The 120 VP5 trimers form a globular structure that 
is positioned around VP7 in the 3-fold axis and sitting below VP2. VP5 interacts with 
both VP2 and VP7, which is consists to what has be observed with BTV (Hyatt, Zhao 
et al. 1993, Mertens, Diprose et al. 2004, Zhang, Boyce et al. 2010, Manole, 
Laurinmäki et al. 2012). 
 
Figure 1.4 Three-dimensional reconstruction of AHSV virus structure. VP2 trimers locate on the 
surface of the viral particle (Manole, Laurinmäki et al. 2012). Reproduced with permission. 
 
1.2.4 Outer capsid proteins: VP2 and VP5 
VP2 and VP5 are involved in cell attachment and membrane penetration (Hassan and 
Roy 1999, Hassan, Wirblich et al. 2001). VP2 is the most variable AHSV protein and 
determines the virus serotype. The neutralizing epitopes of AHSV have been mapped 
to a few discreet regions on the VP2 molecule (Burrage, Trevejo et al. 1993, 
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Martinez-Torrecuadrada, Iwata et al. 1994, Bentley, Fehrsen et al. 2000). AHSV 
exists in nature as 9 distinct serotypes (AHSV-1 to -9) based on differences in VP2 
(McIntosh 1958, Howell 1962, Martinez-Torrecuadrada, Iwata et al. 1994, Scanlen, 
Paweska et al. 2002). As VP2 sits on the surface of the viral particle and is the target 
of neutralising antibodies, it is proposed that high immune pressure results in the 
development of antigenic variants positive selection and serotype diversity (Roy 
1992, Nason, Rothagel et al. 2004, Calvo-Pinilla, de la Poza et al. 2014). Although 
there are 9 distinct AHSV serotypes, there is cross-reactive of neutralising antibodies 
detected. Serotypes pairs that have exhibited cross-neutralising in vitro included 
AHSV-3 and -7, -5 and -8, and -6 and -9 (Mellor and Hamblin 2004, Kanai, Van Rijn 
et al. 2014). 
The VP2 protein of orbiviruses also has haemagglutinating activity, suggesting that 
the protein has a role in determining host range (Cowley and Gorman 1989, Cowley 
and Gorman 1990). Previous studies on BTV demonstrated that VP2 is involved in 
virus entry and exit of the cell via its interaction with NS3 (Hassan and Roy 1999, 
Beaton, Rodriguez et al. 2002, Meiring, Huismans et al. 2009). Structural analysis of 
BTV VP2 revealed a sialic acid binding domain in the hub of VP2 (Zhang, Boyce et al. 
2010) and studies by Manole et al. (Manole, Laurinmäki et al. 2012) indicate that 
AHSV may have a similar region. They suggest that VP2 binds the oligosaccharides in 
cell surface glycoprotein to enable entry. Cleavage of VP2 by proteases blocks the 
virus haemagglutinating activity, however, the infectivity of infectious subviral 
particles (ISVP) is higher for insects in both in vitro and in vivo studies for BTV and 
AHSV (Mertens, Burroughs et al. 1987, Burroughs, O'Hara et al. 1994, Marchi, 
Rawlings et al. 1995). 
VP5 protein, the second outer capsid protein, is postulated to be a type 1 fusion 
protein based on its high structural similarity to BTV-1 VP5 (Manole, Laurinmäki et 
al. 2012). Studies on BTV VP5 have indicated that VP5 has pH-dependent fusion 
activity (Forzan, Wirblich et al. 2004) and is activated in the low pH environment of 
the late endosome allowing the virus core to enter the cytosol (Patel, Mohl et al. 
2016). Expression studies of AHSV VP5 demonstrated that it was cytotoxicity and had 
membrane destabilising capacity, similar phenotype to BTV (du Plessis and Nel 1997, 
Stassen, Huismans et al. 2011). Mutagenesis of AHSV VP5 highlighted that the 
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predicted two amphipathic α-helices at the N-terminal of the protein were essential 
for its fusogenic activity (Stassen, Huismans et al. 2011). Structural studies 
confirmed that the protein did, indeed contain at least amphipathic α-helices 
(Manole, Laurinmäki et al. 2012). Although VP5 is less exposed than VP2, it can elicit 
neutralising antibodies (Martínez-Torrecuadrada, Langeveld et al. 1999). 
1.2.5 Core proteins: VP3 and VP7 
The core particle is a highly stable structure that does not disassociate in the 
cytoplasm of the infected cell (Mertens and Diprose 2004). This prevents the dsRNA 
genome from exposure to pattern recognition (PAMPs) by the host cell. Expression 
of VP3 and VP7 in baculovirus indicates that it could autoassemble into core-like 
particles without the requirement of the transcription complex or genomic RNA 
(Maree, Durbach et al. 1998). The VP3 and VP7 layer interact via their hydrophobic 
surface (both AHSV VP3 and VP7 contain several alanine, methionine and proline 
residues). AHSV VP7 protein is highly hydrophobic and less soluble than BTV or other 
orbivirus VP7 proteins (Roy, Hirasawa et al. 1991). 
During infection and in in vitro studies, AHSV VP7 is highly expressed, and unlike VP7 
from other orbivirus, it forms flat hexagonal crystal sheets or particles that can be 
clearly visualised (Burroughs, O'Hara et al. 1994). Previous studies reported that 
AHSV VP7 is a group-specific immunogenic antigen (Chuma, Le Blois et al. 1992) and 
this is often used in ELISAs designed to differentiate among different orbivirus 
infections. X-ray crystallography reveals that there are two distinct domains in AHSV 
VP7 monomer. The formation of the VP7 trimer structure does not change the 
distribution of the two domains in the particle; the upper interacts with VP2 and the 
lower with VP3 (Basak, Grimes et al. 1997). The β sheet structure of the upper 
domain also contains an Arg-Gly-Asp (RGD) tripeptide motif. The RGD motif has been 
shown to be important for viral entry via integrin receptors (e.g., FMDV (Logan, Abu-
Ghazaleh et al. 1993, Kotecha, Wang et al. 2017) and JEV (Fan, Qian et al. 2017)). 
It is postulated that the VP7 RGD motif assists entry of orbiviruses into insect host 
cells (Basak, Grimes et al. 1997, Tan, Nason et al. 2001). 
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VP3 is essential for the formation of the core and viral particles as VP7 does not have 
the ability to form the core without VP3 and cannot associate with dsRNA or the 
transcription complex. Other than the structural studies there is very little published 
information on AHSV VP3. Drawing parallels with BTV VP3, we can postulate that 
AHSV VP3 interacts with the transcription complex and ssRNA to enable the 
formation of the core (Grimes, Burroughs et al. 1998, Lourenco and Roy 2011). 
1.2.6 Transcriptional complex proteins: VP1, VP4 and VP6 
Three of the minor core proteins, VP1, VP4 and VP6 form the replicase complexes 
that locate in the core of the AHSV viral particle. As with other AHSV proteins, very 
little functional work has been undertaken and thus assignment of function is based 
on BTV. AHSV VP1 is a putative RNA dependant RNA polymerase that is encoded by 
segment 1 of AHSV (Van Dijk 1982, Roy, Mertens et al. 1994, Vreede and Huismans 
1998). Several motifs required for RNA-dependent RNA polymerase activity have 
been identified in AHSV VP1 (Sankar and Porter 1992). 
 It is the most conserved protein not only in the genus Orbivirus but also in the 
Reoviridae (Vreede and Huismans 1998, Attoui, Billoir et al. 2000, Attoui, Stirling et 
al. 2001). This is highlighted when comparing AHSV-9 and BTV-10 VP1 proteins; these 
proteins share 55.6% and 73.2% aa similarity at the nucleotide and amino acids level 
respectively. The GDD sequence required for activity is in a different region in 
comparison to BTV VP1 (Vreede and Huismans 1998). The biological significance of 
this is still unknown. 
VP4 is also conserved between AHSV and BTV, with 48.5% aa similarity (Noriko, 
Kenichi et al. 1993). VP4 is a putative capping protein, encoded by segment 4 and 
similarly to other AHSV proteins the function assignment is based on its similarity to 
BTV. BTV VP4 was one of the first proteins to be characterised that was able to 
catalyse all of the sets of the capping process to generate a Cap1 (m7GpppG-2’-O) 
at the 5’ end of the nascent viral transcripts (Martinez-Costas, Sutton et al. 1998, 
Ramadevi, Burroughs et al. 1998, Stewart and Roy 2015). BTV VP4 possess RNA 
triphosphatase, guanylyltransferase, guanine-N7-methyltransferase and nucleoside-
2'-O-methyltransferase activity (Ramadevi, Burroughs et al. 1998, Sutton, Grimes et 
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al. 2007). This cap is identical as eukaryotic mRNAs, (Mertens and Diprose 2004). 
The first step of the capping pathway, RNA triphosphatase activity, has been 
described for AHSV recombinant VP4 (Van den Bout 2005). 
As the AHSV genome is composed of double-stranded RNA, it requires a protein with 
helicase activity to unwind the strands to allow VP1 to synthesize new transcripts. 
AHSV VP6 is able to bind specifically dsRNA (de Waal and Huismans 2005) and is 
hypothesised, based on similarity to BTV VP6, to have helicase activity. BTV VP6 has 
affinity for both dsRNA and other nucleic acids (Roy, Adachi et al. 1990) and ATPase 
and helicase activity (Stäuber, Martinez-Costas et al. 1997). BTV VP6 is a hydrophilic, 
basic protein. The aa sequence of VP6 is conserved at the C-terminus where the RNA 
binding domain locates. Sequencing analysis indicates that AHSV VP6 contains this 
conserved domain at the same location (Turnbull, Cormack et al. 1996).  
1.2.7 Non-structural proteins of AHSV: NS1, NS2, NS3 and S10-ORF2 
Besides the 7 structural proteins, AHSV has been shown to encode up to 4 non-
structural proteins. These 4 non-structural proteins, NS1, NS2, NS3 and NS4, play 
essential roles in the viral life cycle. 
NS1 is encoded by segment 5 and it is the largest and most abundantly expressed 
non-structural protein of orbivirus with up to 25% of the total viral proteins in BTV-
infected cells (Huismans and Els 1979). The aa sequence of NS1 is highly conserved 
among Orbivirus members: 50–60% aa similarity among BTV, AHSV and EHDV (Van 
Dijk and Huismans 1988, Wilson 1994). AHSV NS1 sequences share up to 96% aa 
similarity (Maree and Huismans 1997). AHSV NS1 forms tubules structures which are 
~23 nm in diameter and 4 microns in length (Maree and Huismans 1997). This is half 
the size of the 52.3 nm tubules structure formed by BTV NS1. In each turn of the 
BTV tubule there are 22 NS1 dimers (Hewat, Booth et al. 1992, Hewat, Booth et al. 
1992). NS1 tubules assembly seems to be independent, as the tubules are observed 
when NS1 is expressed separately in the cell from other viral proteins for both AHSV 
and BTV (Urakawa and Roy 1988, Maree and Huismans 1997). Mutational analysis of 
the analysis of BTV NS1 revealed that the conserved cysteine residues in NS1 at aa 
337 and 340, and N’ and C terminal of the protein are critical for tubule formation 
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(Monastyrskaya, Gould et al. 1995). These two cysteine residues are also conserved 
in the same position in the AHSV NS1 sequence. 
NS1 is predominantly expressed in the cytoplasm of infected cells, whereas a small 
amount is found in viral inclusion bodies (Huismans and Els 1979, Brookes, Hyatt et 
al. 1993). In BTV-infected cells, NS1 forms a tubule structure within the cytoplasm 
(Urakawa and Roy 1988). NS1 is abundantly translated early in virus replication, 
therefore their association with intermediate filament components of the cellular 
cytoskeleton (Eaton, Hyatt et al. 1987) and association of virion and core particles 
with tubules (Eaton, Hyatt et al. 1988), suggest that NS1 may be involved in virus 
replication and/or virus translocation (Eaton, Hyatt et al. 1990). Knock-down of BTV 
NS1 decreased virus induced CPE and virus budding via the plasma membrane has 
led some to hypothesis that it is a viral virulence factor (Owens, Limn et al. 2004) 
and indeed, reassortment of different NS1 proteins increases viral virulence (Meiring 
2011). Recently, BTV NS1 has been shown to increase viral protein synthesis by 
binding the UTRs of viral mRNA (Boyce, Celma et al. 2012). BTV NS1 appears to 
provide a translational advantage of viral transcripts translation over host mRNAs. 
This may explain, in part, the shutdown of host protein synthesis after BTV infection. 
NS1 has also been shown to stimulate the immune response in the host however, it 
is not involved in antibody neutralisation (Roy, Urakawa et al. 1990). A recent study 
showed that AHSV NS1 is a key protein in vaccine composition for protection of IFNAR 
(-/-) mice (de la Poza, Calvo-Pinilla et al. 2013). This is different to vaccine studies 
with BTV, probably due to the strong CTL response raised by AHSV NS1. 
NS2 is a highly conserved non-structural protein that is highly expressed in orbivirus-
infected cells (van Staden and Huismans 1991). NS2 is encoded by segment 8 and is 
the only phosphorylated viral protein translated by BTV and AHSV (Devaney, Kendall 
et al. 1988). It is a major component of viral inclusion bodies (VIBs) (Brookes, Hyatt 
et al. 1993). Expression of AHSV NS2 from recombinant baculovirus in insect cells 
results in the formation of dense granular bodies or VIBs (Uitenweerde, Theron et 
al. 1995). The phosphorylation state of BTV NS2 has been shown to be critical for 
the formation of the VIBs. Dephosphorylation of NS2 is hypothesised to ‘release’ the 
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subcore and to complete assembly and egress of the particle (Modrof, 
Lymperopoulos et al. 2005, Kar, Bhattacharya et al. 2007). 
VIBs are also rich in viral ssRNA and core structural proteins, thus they are thought 
to be the site of virus replication and assembly (Brookes, Hyatt et al. 1993) (Thomas, 
Booth et al. 1990). AHSV and BTV NS2 both have ssRNA binding ability and are 
thought to recruit viral ssRNA to the VIBs (Uitenweerde, Theron et al. 1995). The 
ability to bind ssRNA was found to be via the N-terminus of the protein in VIBs, this 
allows NS2 to form dimers (Fillmore, Lin et al. 2002, Kar, Bhattacharya et al. 2007). 
More in-depth RNA binding studies of BTV NS2 demonstrated it had the capacity to 
discriminate between viral and host cell ssRNA based on the unique RNA structures 
in the viral RNA species (Lymperopoulos, Noad et al. 2006). 
The smallest dsRNA segment of virus genome, segment 10, encodes two forms of 
NS3, NS3 and NS3A (van Staden and Huismans 1991). NS3A translation is initiated to 
the secondary start codon, 10 aa downstream of NS3 and it is proposed to occur via 
leaking scanning (van Staden and Huismans 1991). There are conserved regions 
within AHSV NS3/NS3A, which are also found in other orbivirus NS3/NS3A proteins 
(Bansal, Stokes et al. 1998, Van Niekerk, Freeman et al. 2003, Celma and Roy 2009). 
The conserved regions include: a proline rich region, a highly conserved region, two 
hydrophobic/transmembrane domains and a highly variable domain which is flanked 
by two transmembrane domains.  
The expression of recombinant NS3 proteins or in infected cells is lower than the 
other non-structural proteins NS1 and NS2 (French, Inumaru et al. 1989, Van Staden, 
Stoltz et al. 1995, Celma and Roy 2009). In addition, for BTV NS3, the amount 
synthesised is cell type dependent (French, Inumaru et al. 1989). NS3/NS3A localises 
to the cell membrane of infected cells (Van Staden, Stoltz et al. 1995) and as AHSV 
NS3 localises to sites of virus release, it is proposed to have a role in membrane 
destabilisation to allow the virus to exit (Stoltz, Van der Merwe et al. 1996). BTV 
NS3/NS3A has shown to have a role in egress of the virus and release via budding 
(Hyatt, Zhao et al. 1993, Wirblich, Bhattacharya et al. 2006, Celma and Roy 2009). 
Although, BTV has a late lytic cycle to allow release of the virus, the early budding 
from mammalian cells is thought to assist in cell to cell spread early in infection 
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(Celma and Roy 2009) (Bhattacharya and Roy 2010). It may also have a role in virus 
egress in insect cells as the virus infection is non-lytic. It is also proposed that AHSV 
NS3/NS3A is a viral virulence factor. Overexpression of AHSV NS3 in insect cell was 
cytotoxic and increased cell membrane permeability (Stoltz, Van der Merwe et al. 
1996). The cytotoxic nature of AHSV NS3 is mediated by the two transmembrane 
domains (van Niekerk, Smit et al. 2001).  
AHSV NS3/NS3A is the second most variable viral protein after VP2 with up to ~28% 
to ~37% aa difference across the different serotypes (van Niekerk, Smit et al. 2001). 
The driving force behind the high level of variation in NS3 is unknown as expression 
is low in infected cells. Sequence analysis of the NS3 aa acid sequences revealed 
that they cluster into 3 distinct phylogenetic clades (,  and ) (Sailleau, Moulay et 
al. 1997, Martin, Meyer et al. 1998, van Niekerk, Smit et al. 2001, Quan, Van Vuuren 
et al. 2008). These clades have been implicated in the potential virulence of AHSV 
(Martin, Meyer et al. 1998, O’Hara, Meyer et al. 1998). Viral reassortment studies, 
prior to the development of a reverse genetics system for AHSV, verified that AHSV 
NS3 had a key role in virus release and permeabilization of the cell membrane 
(Meiring, Huismans et al. 2009). Meiring and colleagues demonstrated that viruses 
expressing NS3 had the greatest ability to permeabilise the cell membrane followed 
by NS3 and NS3. This effect was only observed in mammalian cells and not in 
insect cells. Although, AHSV NS3 has been shown to have a role in virus release, 
reverse genetic-engineered viruses that did not express NS3 could replicate 
efficiently in BSR cells but not in the insect vector cell line (Van de Water, van 
Gennip et al. 2015). The mutational analysis of NS3 also supported previous findings 
that NS3 had a role in virus cytotoxicity (Van de Water, van Gennip et al. 2015). 
The most recent putative non-structural protein to be identified was segment 10 
ORF2 which was identified using bioinformatics (Sealfon, Lin et al. 2015, Stewart, 
Hardy et al. 2015). An ORF was identified in all 230 AHSV segment 10 sequences 
analysed, ranging from 60–83 aa in length (Stewart, Hardy et al. 2015). No further 
analysis has been published studying the function of this ORF in AHSV although in 
BTV is not required for replication in mammalian or insect cell lines and may have a 
role in host cell protein shutdown (Stewart, Hardy et al. 2015). 
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1.2.8 Non-structural protein 4, NS4 
NS4, originally referred to as ORFX, was identified by bioinformatics in +1 reading 
frame of segment 9 of several orbiviruses (AHSV, BTV, GIV, PALV, PHSV, SCRV and 
YUOV) overlapping the major ORF encoding VP6 (Firth 2008, Belhouchet, Jaafar et 
al. 2011). Initial bioinformatics data identified only one form of putative ORF (ORFX) 
in the AHSV genome, whereas Zwart et al. analysis revealed that this ORF split into 
2 distinct phylogenetic clades and referred to the products as NS4-I and NS4-II. This 
nomenclature was based on the equivalent protein in BTV (Zwart, Potgieter et al. 
2015) as no experiments have been published demonstrating that AHSV NS4 is a non-
structural protein. Both types of AHSV NS4 have been detected in the spleen, lung 
and heart from infected animals and in vitro expression studies demonstrated that 
it localised predominantly to the cytoplasm but was also detected in the nucleus 
(Zwart, Potgieter et al. 2015). This was slightly different to BTV NS4, which only has 
one form and localises predominantly to the nucleolus (Ratinier, Caporale et al. 
2011). Zwart et al. also demonstrated that NS4 was able to protect DNA from specific 
DNAse treatment but not dsRNA, although there were no controls using protein 
known to protect the dsRNA or DNA and no interaction assays such as EMSA were 
undertaken to prove an interaction. The main functional role of AHSV NS4 is still 
unknown. 
BTV NS4 has been studied in greater depth thanks to the development of a reverse 
genetic system. This allows the study of viral proteins without the other factors 
affecting the outcome i.e. the viruses all have the same parental backbone. NS4 is 
expressed at early stages during virus replication (4 h post-infection (Belhouchet, 
Jaafar et al. 2011)) and localised in cell nucleus (Ratinier, Caporale et al. 2011). NS4 
was shown to be dispensable for viral replication in the insect vector and mammalian 
cells in vitro and in vivo (Ratinier, Caporale et al. 2011), however it was shown to 
confer a replicative advantage in interferon competent cell lines and animals 
(Ratinier, Caporale et al. 2011, Ratinier, Shaw et al. 2016). Moreover, in vitro 
studies demonstrated that BTV NS4 downregulated the expression of a firefly 
luciferase from several different promoters and this activity specifically localised to 
the nucleolus of the cell (Ratinier, Shaw et al. 2016). The data for BTV NS4 suggest 
that it is an interferon antagonist and may have a role in viral pathogenesis (Ratinier, 
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Caporale et al. 2011, Ratinier, Shaw et al. 2016). The aim of this thesis is to 
investigate the biological functions of AHSV NS4. 
1.3 AHSV replication 
Different viruses use various mechanisms to enter the cell. Viruses penetrate the 
plasma membrane and ultimately release viral genome into cytoplasm directly. 
Enveloped viruses fuse their envelopes with cell membrane to release the viral 
particle into cytoplasm. While non-enveloped viruses enter cells via clathrin-
mediated uptake, caveolae-mediated endocytosis, lipid raft-mediated endocytosis, 
receptor-mediated endocytosis or macropinocytosis (Pelkmans and Helenius 2003). 
The first step of virus infection is the attachment of virions onto the receptors of 
the cell surface (Figure 1.5). No specific receptor(s) have been reported for any 
orbivirus while these viruses have been shown to entry and replicate in a wide range 
of different cells. It is suspected that BTV VP2 interacts with sialic acid on the cell 
surface to initiate entry (Zhang, Boyce et al. 2010) via clathrin-mediated endocytosis 
(Eaton, Hyatt et al. 1990, Hassan and Roy 1999, Forzan, Wirblich et al. 2004, Forzan, 
Marsh et al. 2007) in HeLa and Vero cells. Further studies of BTV in BHK cells also 
demonstrated that it was able to enter cells via clathrin and cholesterol-
independent mechanisms that also required dynamin (Gold, Monaghan et al. 2010) 
indicating that it may enter via macropinocytosis. Until recently the entry strategy 
of AHSV was unknown and inferred based on BTV. Recently AHSV has been shown to 
enter BSR cells via macropinocytosis (Vermaak, Conradie et al. 2016) and does not 
require caveolin- or clathrin-dependent endocytosis. Entry was shown to be 
dependent on dynamin in BHK-21 cells. Recent reverse genetic experiments 
including truncations of AHSV VP2 demonstrated that it is not required for entry into 
BSR, Vero or Kc cells (Van Gennip, van de Water et al. 2017) indicating that there 
are multiple entry strategies used by AHSV to infect cells. 
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Figure 1.5 A schematic cartoon of the replication cycle of BTV (Mertens and Diprose 2004). 
Reproduced with permission. 
The mechanism used by AHSV to leave the endosome is still unknown and is inferred 
based on BTV studies. Once the particle enters the endosome, VP2 is shed in the 
early endosome and virus particles containing VP5 are trafficked to late endosomes 
(Du, Bhattacharya et al. 2014) for further transfer to liposomes (Patel, Mohl et al. 
2016). The low pH of liposomes causes VP5 to change conformation allowing the 
release of core particles into the cytoplasm (Hassan, Wirblich et al. 2001, Forzan, 
Wirblich et al. 2004, Patel, Mohl et al. 2016, Zhang, Patel et al. 2016). 
Like other reoviruses, BTV and AHSV replicate in the cytoplasm of infected cells. 
The AHSV core is a transcriptionally active (Matsuo, Celma et al. 2010) and the 
genomic dsRNA is not released into the cytosol stopping early activation of the host 
cell anti-viral system and triggering IFN production (Marcus and Sekellick 1977). The 
core particle of AHSV contains all the necessary enzymes to initiate transcription 
and cap the nascent transcripts. Before transcription initiation, the genome dsRNA 
must be unwound by the viral helicase, VP6 (de Waal and Huismans 2005), which 
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allows the RNA dependent RNA polymerase (VP1) to start producing the transcripts 
(Vreede and Huismans 1998). The transcription is asymmetric and only positive sense 
RNA molecules are synthesised from the negative strands of viral genome dsRNA. 
These newly synthesised ssRNAs are capped and methylated at 5’ end by VP4, which 
is the capping enzyme (Van den Bout 2005), and become ‘mature’ mRNAs. The 
materials and substrates required for the transcription and capping activities, 
including S-adenosylmethionine (SAM) nucleotide triphosphates (NTPs), and the by-
products, for example S-adenosyl-l-homocysteine (SAH) and adenosine diphosphate 
(ADP) are transferred into and out of the core particle by alternative channels 
(Diprose, Burroughs et al. 2001) (Figure 1.6). It is hypothesised, based on studies 
using rotavirus, that each transcript is simultaneously made and exits the core 
particle from transcript specific pores at the 5-fold axis of the particle (Periz, Celma 
et al. 2013). 
 
 
Figure 1.6 Schematic cartoon representing BTV transcription in the core particle. The dsRNA 
segment is transcribed by a transcription complex and mature capped mRNA is extruded via 
the translocation portal into the cytoplasm. The substrates, including SAM and NTP, and the by-
products, including SAH and ADP, of the transcription machinery are transferred by alternative 
pores (Mertens and Diprose 2004). Reproduced with permission. 
 
 42 
 
After released into the host cell cytoplasm from the viral core particle, the capped 
viral mRNAs start to be translated by recruitment of host cell translation complex at 
the capped 5’ end. In mammalian cells, the mature mRNA contains a polyadenylated 
poly(A) tail at the 3’ end, which interacts and is bound to a poly(A) binding protein 
(PABP). PABP interacts with the translation complex to stabilise the mRNA and 
regulate translation (Drummond, Armstrong et al. 1985, Gallie 1991). mRNAs of AHSV 
and other reoviruses do not contain a poly(A) tail, however in BTV, the inverted 
repeats in UTR region of viral mRNA possibly interact with PABP and allow the viral 
mRNA to be translated (Markotter, Theron et al. 2004). Recent work with BTV NS1 
indicates that it aids with the up-regulation of viral protein translation (Boyce, 
Celma et al. 2012), therefore NS1 is hypothesised to interact with cellular PABP or 
elongation.  
During replication, large VIB is consisting of mainly NS2 (Huismans and Els 1979, 
Venter, Van der Merwe et al. 2014). These VIB are viral ssRNA and the viral proteins 
VP1, VP3, VP4, and VP6 and are proposed to be the site of sub-core assembly (Roy 
1996). For BTV, it has been demonstrated that VP6 recruits ssRNA. This allows the 
interaction of VP6 with the inner surface of the VP3 decamer and then it recruits 
VP1 and VP4 to assemble the particle. Synthesis of the dsRNA genome occurs within 
the sub-core (Grimes, Burroughs et al. 1998, Nason, Rothagel et al. 2004, Lourenco 
and Roy 2011). The exact mechanism by which the ssRNA is packaged is still 
unknown, however it has been demonstrated for BTV that VP6 is essential for ssRNA 
packaging (Matsuo and Roy 2009) and that ssRNA is recruited in a segment- and 
sequence-specific manner (Burkhardt, Sung et al. 2014, Sung and Roy 2014, Boyce, 
McCrae et al. 2016). Once the sub-core has been released from the VIB, it acts as a 
scaffold for the addition of VP7. 
The assembly of the mature particle and egress of AHSV is also based on BTV and 
there have only been a couple of studies examining this process (Bhattacharya, Noad 
et al. 2007, Bhattacharya and Roy 2008). After the sub-core particle leaves the VIB, 
VP7, VP5 and VP2 are assembled in succession to form the outer capsid of the virus 
and form mature progeny virus (Roy 1996). VP7 has been detected around the VIB 
and it is thought that the interaction between VP3 and VP7 is via hydrophobic 
interactions. VP5 is associated with lipid rafts and its integrity is critical for the 
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assembly of the virion (Bhattacharya and Roy 2008). The interaction between BTV 
VP2 and vimentin is involved in the transport of BTV viral particles cell microtubules 
within the cytoplasm (Bhattacharya, Noad et al. 2007), while NS3 mediates viral 
particle movement to the cell surface (Beaton, Rodriguez et al. 2002, Celma and 
Roy 2009). AHSV NS3 has been shown to increase cell membrane permeability 
(Meiring, Huismans et al. 2009), which contributes to the release of the viral particle 
to the environment from the host cell. Furthermore, NS3 also recruits the ESCRT-I 
protein and interacts with the vacuolar sorting pathway (Hurley and Emr 2006), 
which results in the budding of BTV a temporary envelope (Stoltz, Van der Merwe et 
al. 1996).  
Once released, the new mature viral particles can infect new cells to start a new 
replication cycle or ‘superinfect’ the same cell (Hyatt, Eaton et al. 1989). 
 
1.4 Immune response to AHSV infection 
Currently, the knowledge of the host immune response to AHSV infection is limited. 
As AHSV and BTV belong to the genus Orbivirus and share similarities in their viral 
structures and protein functions, the results from BTV studies will be used to infer 
the information of AHSV. 
1.4.1 Innate immune response 
The innate immune response constitutes the first line of defence against virus 
infection. The mechanism is not specific to any given pathogen and relies on cellular 
sensors to detect foreign or non-self objects in the cell and it occurs rapidly after 
the onset of infection. There are several different types of innate immunity including 
intrinsic innate immunity where existing cellular factors directly restricts virus 
replication (for example, Vif and APOBEC (Malim 2006)). To date no one has 
published any information of host cell restriction factors against either AHSV or BTV. 
Another arm of the innate immune response is the indirect restriction of viral 
infection by inducing interferons and up-regulating the expression of other antiviral 
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molecules. Apoptosis, pyroptosis and necroptosis are also mechanisms used by the 
cell after sensing virus infection in order to restrict replication and virus spread.  
Cell death by necroptosis and apoptosis has been reported for both AHSV and BTV 
(DeMaula, Jutila et al. 2001, DeMaula, Leutenegger et al. 2002, Mortola, Noad et al. 
2004, Nagaleekar, Tiwari et al. 2007, Stewart and Roy 2010, Stassen, Huismans et 
al. 2012, Vermaak and Theron 2015). In the case of BTV, outcome seems to be highly 
dependent on cell type with primary cells undergoing necrosis (DeMaula, Jutila et 
al. 2001, DeMaula, Leutenegger et al. 2002) and transformed cell lines undergoing 
apoptosis (Mortola, Noad et al. 2004, Stewart and Roy 2010). Unlike BTV, where 
exposure of cells to the outer capsid proteins was sufficient to trigger an apoptotic 
response, AHSV-induced apoptosis required entry of the virus into the cytosol 
(Vermaak and Theron 2015). Both the intrinsic (caspase-9) and extrinsic (caspase-8) 
pathways have been shown to be triggered by orbiviruses (Stewart and Roy 2010, 
Stassen, Huismans et al. 2012). 
Infection of animals with BTV has been demonstrated to initiate a cytokine storm 
(DeMaula, Jutila et al. 2001, DeMaula, Leutenegger et al. 2002, Hemati, Contreras 
et al. 2009, Drew, Heller et al. 2010). Experiments using PMBCs isolated from horse 
and infected with AHSV-4 were also demonstrated to release a number of cytokines 
indicating that a cytokine storm is probable during the initial phase of AHSV infection 
prior to the induction of the adaptive immune response (Sánchez-Matamoros, 
Kukielka et al. 2013). BTV infection activates the production of inflammation and 
immune cytokines in the host cells, for example interleukins (IL)-1, IL-6, IL-12 and 
tumour necrosis factor α (TNFα) (Hemati, Contreras et al. 2009, Drew, Heller et al. 
2010). Further, BTV dsRNAs are also recognised by host cell toll-like receptors (TLRs) 
and/or retinoic acid inducible gene (RIG-I)-like family triggering downstream cell 
signalling pathways and inducing the production of interferons (IFN) and pro-
inflammation cytokines (Levy, Marié et al. 2011). 
The induction of IFN in response to AHSV infection has not been studied. To date, 
there is only one report eluding to the role of IFN in controlling AHSV infection (de 
la Grandière, Dal Pozzo et al. 2014). BTV is shown to induce a strong type-I IFN 
production both in vivo and in vitro (MacLachlan and Thompson 1985, Russell, 
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O'Toole et al. 1996) and it is hypothesised that AHSV infection could also induce a 
strong IFN response. In BTV-infected endothelial cells, type-I IFN production is 
activated following RIG-I and MDA5-mediated signalling (Chauveau, Doceul et al. 
2012). BTV infection is non-lethal in IFN competent adult mice, whereas in IFN 
receptor knockout mice (IFNAR (-/-)) mice, both BTV and AHSV infections are lethal 
(Calvo-Pinilla, Rodríguez-Calvo et al. 2009, de la Grandière, Dal Pozzo et al. 2014).  
The innate immune system does not provide a long-lasting immune protection for 
the host. In experimentally infected sheep, IFN starts to be detectable in serum at 
about 4-days post p.i. and the IFN concentration reaches a peak between 4 and 8 
days p.i. Then, the concentration decreases rapidly at about 10 days p.i. (Foster, 
Luedke et al. 1991). But the type-I IFN that is produced by the innate immune system 
further triggers B cell responses and therefore promotes humoral immunity to 
generate antibodies against BTV (Deal, Lahl et al. 2013). 
1.5 Cellular immune response 
Cell-mediated immunity (CMI) limits virus spread by targeting and destroying 
infected cells. Antibodies are not part of the cellular immune response. CD4+ cells 
provide protection against exogenous pathogens and guide the transformation of 
naive T cells into activated effector T cells. T cells respond to antigens presented 
on major histocompatibility molecules (MHCs), including from professional antigen-
presenting cells (APCs) such as dendritic cells (Iwasaki and Medzhitov 2004). BTV-
specific CD8+ T-cells develop in both sheep and mouse following BTV infection. In 
general, the CD8+ T cell population increases after 10–15 day p.i. (Ghalib, Schore et 
al. 1985, Sanchez-Cordon, de Diego et al. 2015), whereas short-lived anti-BTV 
cytotoxic T-lymphocytes (CTL) develop at 12 to 14 days p.i. (Jeggo, Wardley et al. 
1984). Previous studies demonstrated that transfer of CTLs from the thoracic duct 
of sheep previously infected with BTV to recipient sheep can provide partial 
protection from either homologous or heterologous serotypes of BTV (Jeggo, 
Wardley et al. 1984).  
The BTV VP2 and NS1 proteins have been identified as major targets for the host CMI 
response in sheep, with the NS1-specific CTL response playing a primary role in 
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serotype cross-protection (Andrew, Whiteley et al. 1995, Janardhana, Andrew et al. 
1999). In contrast, both NS1- and NS2-specific CTLs develop in BTV infection of mice 
(Jones, Williams et al. 1997).  
1.6 Humoral immune response 
Antibodies to both structural and non-structural proteins are produced following 
infection by BTV and AHSV (Richards, MacLachlan et al. 1988, Hamblin, Anderson et 
al. 1992). In particular, neutralising antibodies block virus infection by targeting 
epitopes within the outer capsid protein VP2 of BTV and AHSV. However, as VP2 is 
the most antigenically diverse protein of BTV and AHSV, there is a lack of cross 
protection against infection across different serotypes. For BTV, the presence of 
common epitopes has been proven and neutralising antibodies are found to exert a 
level of cross reactivity among several BTV serotypes (Rossitto and MacLachlan 
1992). The heterotypic antibody response is not efficient during co-infections with 
multiple viruses (Jeggo, Wardley et al. 1984). 
1.7 Type I IFN production in response to virus infection 
IFNs are composed by a group of proteins that are involved in cell signalling pathway 
regulation. IFNs are released by host cells in response to pathogens, including virus, 
bacteria, and parasites. To date, three major types of IFN have been identified 
based on the type of receptor. Amongst these, type I IFN is the most important 
against virus infections (Parkin and Cohen 2001). Type I IFN proteins in human 
comprise several subclasses but share the same cell surface receptor, IFN-α/β 
receptor (IFNAR) (Novick, Cohen et al. 1994). In human, Type I IFNs include IFN-α, 
IFN-β, IFN-ε, IFN-κ and IFN-ω (de Weerd, Samarajiwa et al. 2007). IFN proteins 
themselves do not have antiviral functions, however, they induce the transcription 
of downstream genes which act as antiviral effectors (Pestka, Krause et al. 2004). 
When viruses infect cells, IFN production is induced. The production of IFN is 
triggered following the recognition of pathogen associated molecular patterns 
(PAMPs). Generally, there are three types of nucleic acid-based PAMPs during 
pathogen infection: dsRNA, ssRNA and non-methylated CpG DNA. Moreover, there is 
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one type of lipid-based PAMP: lipopolysaccharide (LPS) (Brentano, Kyburz et al. 
2005). These PAMPs are detected by pattern recognition receptors (PRRs). These 
receptors are involved in distinguishing self from non-self-material and promoting 
the antiviral response to exogenous pathogens. To date, two major families of PRRs 
have been characterised in virus detection: Toll-like receptors (TLRs) and RIG-I-like 
receptors (RLRs) (Akira, Uematsu et al. 2006).  
TLRs are activated in response to extracellular and endosomal PAMPs, and trigger a 
variety of downstream defence mechanisms based on cell type and receptors. To 
date, 13 TLRs have been identified in human and mouse (Thompson and Locarnini 
2007). TLRs are mainly expressed by antigen presenting cells, for example 
macrophages, whereas other cell types also express a subset of TLRs (Akira, Uematsu 
et al. 2006). TLRs share a common organization, including a leucine-rich repeat 
extracellular domain (LRR), a transmembrane domain, and a Toll/interlukin-1 
receptor domain (TIR). The LRR domain is involved in PAMP recognition, whereas the 
TIR domain interacts with TIR domain-containing adaptors (Yamamoto, Takeda et 
al. 2004). Activation of TLRs results in the dimerization of receptors and the 
recruitment of adaptors, in turn triggering multiple downstream signalling pathways, 
resulting in the synthesis of IFN and pro-inflammatory cytokines (O'Neill and Bowie 
2007). Of the recognised TLRs, TLR3, TLR7/8 and TLR9 are the most important ones 
for the host innate immune response against viral infection. 
TLR3 recognises dsRNA as a PAMP. Double-stranded RNA is considered as the most 
important PAMP of infections by Group III viruses such as orbiviruses. During viral 
infection, dsRNAs sometimes appear as intermediates of virus replication or 
structured RNA, whereas the host cell is not able to generate dsRNA. By binding and 
interacting with dsRNA, TLR3 can recruit and activate the downstream adaptor TRIF, 
subsequently activating the transcription factors IRF-3/7, NF-κB and AP-1 
(Yamamoto, Sato et al. 2003, Vercammen, Staal et al. 2008). IRF-3/7 is essential for 
IFN-β expression (Sato, Suemori et al. 2000). By interacting with TRAF3, TRIF 
activates TBK1 and IKKε kinases. The resulting phosphorylation and dimerization 
leads to the activation of the transcription factors IRF-3/7. Activated IRF-3 and -7 
then translocate into the cell nucleus and induce the transcription of the IFN-β gene 
(Panne, Maniatis et al. 2007). IRF-3 and IRF-7 play different roles in IFN-α/β gene 
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transcription. Briefly, IRF-3 expression is engaged at an early stage of viral infection, 
whereas IRF-7 is involved in IFN release and plays an important role in the IFN 
positive feedback loop (Honda, Yanai et al. 2005, Hiscott 2007). TRIF also interacts 
with TRAF6 and RIP1 to active NF-κB and AP-1, which are both regulators of 
transcription of the various inflammatory cytokine genes. Briefly, TRAF6 and RIP1 
activate the MAPK pathway, which results in activation of AP-1. This MAPK pathway 
also regulates the IKK complex, the activation of which results in the 
phosphorylation and degradation of the IκBα inhibitor. The released NF-κB can 
translocate into the cell nucleus to induce the inflammatory response (Alexopoulou, 
Holt et al. 2001, Peng, Yuan et al. 2010).  
When TLR7/8 binds ssRNA in the endosomal compartments, they recruit and activate 
the adaptive molecule MyD88 via their TIR domain. The activated MyD88, combined 
with IRAK-1 and IRAK-4 kinases, forms a complex to induce IRF-7 phosphorylation 
and activate the NF-κB pathway with TRAF6 (Oganesyan, Saha et al. 2006). The PAMP 
of TLR9 is non-methylated CpG DNA that originates from bacterial or viral genomes 
(Eisenächer, Steinberg et al. 2008). Similar to TLR7/8, TLR9 also induces the 
upregulation of IFN-α/β expression via IRF-7 activation and provokes the activation 
of the NF-κB pathway (Fiola, Gosselin et al. 2010). 
1.7.1 Receptors of viral infection in the cytoplasm 
The RIG-I-like receptor pathway is considered to be an alternative cellular innate 
immune system for the detection of intracellular viral infections. It is reported that 
the helicases RIG-I and MDA5 are able to detect intracellular dsRNA and act as PRRs 
in order to induce IFN-β production and trigger inflammatory cytokine expression 
(Yoneyama, Kikuchi et al. 2004, Chauveau, Doceul et al. 2012). These RIG-I-like 
receptors (RLRs) share a similar structure, including a helicase domain, a C-terminal 
domain (CTD) and two CARD domains at the N-terminus. RIG-I additionally has as a 
repressor domain that is absent in MDA5 (Takahasi, Kumeta et al. 2009). RIG-I and 
MDA5 are expressed and trigger IFN production in most types of cells, including 
fibroblast and conventional dendritic cells (cDCs). However, in pDCs, where TLRs 
are highly expressed, the cells preferentially use the TLR system (Luber, Cox et al. 
2010) (Kato, Sato et al. 2005).  
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Although the aa sequence similarity between RIG-I and MDA5 is high, the PAMPs of 
these two proteins are different. RIG-I has a higher affinity for ssRNA as opposed to 
dsRNA (Saito and Gale 2008, Takahasi, Yoneyama et al. 2008), specifically ssRNA 
with an exposed 5’-triphosphate (Takahasi, Yoneyama et al. 2008, Schmidt, Schwerd 
et al. 2009). As 5’-triphosphate RNAs are not presented in non-infected cells, this 
RNA motif is a strong hallmark of viral infection. Moreover, RNA secondary 
structures, for example base-paired stretches, can also influence the activation of 
RIG-I. The combination of a double strand stretch of RNA, and a 5′-triphosphate 
forms a sufficient PAMP for RIG-I recognition (Schmidt, Schwerd et al. 2009, 
Takahasi, Kumeta et al. 2009). Despite its lower affinity for dsRNA, RIG-I is also 
associated and activated by short dsRNA (<2kb) (Kato, Takeuchi et al. 2008). Unlike 
RIG-I, MDA5 does not bind 5’-triphosphatate ssRNA. However, it has a high affinity 
for dsRNA, in particular long dsRNA (>2kb). Indeed, long dsRNA molecules are 
necessary for MDA5 activation (Kato, Takeuchi et al. 2008). 
In non-infected cells, the activity of RIG-I is maintained in an inactive conformation 
by the RD domain. When the CTD domain of RIG-I binds viral RNA, the conformation 
of the protein is altered and the CARD domain is exposed, thus activating RIG-I. After 
activation, RIG-I interacts with the mitochondrial antiviral signalling protein (MAVS) 
via the CARD domain (Seth, Sun et al. 2005). Following activation by dsRNA, MDA5 
forms dimers and filaments, which also interact with MAVS (Berke and Modis 2012). 
Similarly, to TRIF, activated MAVS interacts with TRAF3 to activate TBK1 and IKKε, 
subsequently activating the IRF-3/7 pathway to trigger IFN-β expression (Saha, 
Pietras et al. 2006). Activated MAVS is able to trigger the NF-κB pathway and 
downstream inflammatory response by associating with TRAF6 (Seth, Sun et al. 
2005).  
1.7.2 Cell response to extracellular type I IFN 
IFN secretion triggers the Janus tyrosine kinase/signal transducer and activator of 
transcription protein (JAK/STAT) pathway in most cell types (reviewed by (Aaronson 
and Horvath 2002, Rawlings, Rosler et al. 2004, Quintás-Cardama and Verstovsek 
2013)). The JAK/STAT pathway is well characterised and activation of this pathway 
results in the downstream gene expression of IFN-stimulated genes (ISGs). The 
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proteins encoded by ISGs play critical roles on cellular functional processes, 
including the innate and adaptive immune systems, cell proliferation and survival, 
and cellular protein synthesis in order to establish an antiviral state. The cell surface 
receptor IFNAR is the receptor for extracellular IFN-α/β. IFNAR is composed of two 
subunits, IFNAR1 and IFNAR2, which are both transmembrane proteins and expressed 
in most of the cell types (de Weerd, Samarajiwa et al. 2007). Binding either IFNAR1 
or IFNAR2 with the type I IFN leads to the recruitment of the other subunit to form 
a dimer. After the dimerization, IFNAR1 and IFNAR2 associate with different 
adaptors. IFNAR1 associates with and phosphorylates tyrosine kinase 2 (TYK2), which 
belongs to the JAK family (Gauzzi, Velazquez et al. 1996), whereas IFNAR2 interacts 
with JAK1 and STAT2 (Uddin, Chamdin et al. 1995, Gauzzi, Velazquez et al. 
1996).The activated JAK1 in turn phosphorylates the IFNAR1 and IFNAR2 on the 
tyrosine residues (Zhao, Lee et al. 2008). This allows the STAT2 protein to bind the 
IFNAR1 on the phosphorylated tyrosine residues. Following STAT2 phosphorylation, 
STAT1 is further phosphorylated by binding STAT2 (Yan, Krishnan et al. 1996). The 
phosphorylated STAT1 and STAT2 dimerise and the STAT1/2 dimer is released from 
IFNAR2 into the cytoplasm. In the cytoplasm, the heterodimer interacts with IRF9 to 
form a protein complex referred to as the transcription factor ISG factor 3 (ISGF3) 
which transfers into the cell nucleus to regulate ISG transcription by binding the 
promoter element ‘IFN-stimulated response element’ (ISRE). STAT is a big protein 
family. Protein STAT1 to STAT6 are all associated with, and can be activated via, 
IFN pathway. However, variation in STAT usage is cell type dependent (Meinke, 
Barahmand-Pour et al. 1996, Matikainen, Sareneva et al. 1999) (Figure 1.7). 
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Figure 1.7 Pathways of interferon induction and signalling. Exogenous viral dsRNA in the 
cytoplasm leads to IFN gene transcription. Secreted type I IFN activates the neighbour’s cells 
JAK/STAT pathway by binding to the IFNAR and ultimately inducing the ISGs expression 
(Fensterl and Sen 2009). Reproduced with permission. 
 
1.7.3 Viruses regulate the host cell type I IFN response 
In order to successfully infect and proliferate in the host, viruses have evolved a 
variety of mechanisms to escape the host immune system. Detection of viral PAMPs 
by cellular PRRs is the first step in generating a host immune response. To avoid 
viral PAMPs being detected by cellular sensors, a frequent strategy for many RNA 
viruses is to protect and hide their genomic RNA inside the viral- or cellular-derived 
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structures such that the genome is not visible to the cellular sensors. Multiple ways 
of blocking PAMP detection have evolved in different viruses. Vaccinia virus 
expresses two proteins, A46 and A52, which are strong antagonists of TLR receptors. 
The A46 viral protein contains a Toll/interlukin-1 receptor domain, and associates 
the adaptors of TLRs, including MyD88, TRIF and TRAM, to prevent the TIR domain 
of the TLRs associating with their adaptors competitively (Stack, Haga et al. 2005). 
On the other hand, the A52 protein of vaccinia virus binds to TRAF6 and IRAK-2 in 
order to stop the NF-κB pathway activation (Harte, Haga et al. 2003). In the infected 
cells, the RIG-I pathway is one of the most important PAMP detection mechanisms. 
As a result, RIG-I-like receptors (RLRs) and their adaptors are common targets of 
viral antagonism. For example, the Influenza A viral protein NS1 binds to the viral 
RNA genome to prevent the viral RNA from being detected by RIG-I (Guo, Chen et 
al. 2007). IRF is another target for viral proteins to inhibit the IFN response. The 
Borna disease virus P protein is phosphorylated by TBK1 and acts as a decoy for host 
IRF-3 phosphorylation (Unterstab, Ludwig et al. 2005).  
To stop the host cell response to extracellular IFN and block antiviral protein 
synthesis, the JAK/STAT pathway is also targeted by viruses. Many viral proteins act 
as antagonists of this pathway to obstruct antiviral response. For example, rhesus 
rotavirus (RRV) is able to block STAT1 and STAT2 translocation to the nucleus in 
order to inhibit the response to type I IFN (Holloway, Truong et al. 2009). Viruses 
can also disrupt IRF9 from forming the ISGF3 complex in order to down regulate the 
JAK/STAT pathway. The μ2 protein from a non-myocarditic strain of reovirus results 
in the accumulation of IRF9 in order to prevent formation of the ISGF3 complex 
(Zurney, Kobayashi et al. 2009), and inhibit downstream ISG expression. By blocking 
the JAK/STAT pathway, viruses also inhibit ISG expression, and subsequently affect 
the positive feedback loop of the IFN response. 
Proteins that are encoded by ISGs play a variety of roles in the antiviral mechanism. 
Therefore, to promote viral replication, viruses inhibit the IFN response. ISGs, 
including protein kinase R (PKR) and oligoadenylate synthetase/RNase L (OAS/RNase 
L), are important host antiviral proteins. Some viral proteins can target these 
proteins to either block their function or induce their degradation. For example, the 
E2 protein of hepatitis C virus contains a homologous sequence to PKR and shares 
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the same phosphorylation sites. The E2 protein is in turn able to target PKR and 
prevent its phosphorylation and activation (Taylor, Shi et al. 1999), whereas human 
immunodeficiency virus (HIV) infection upregulates the expression of RNase L 
inhibitor (RLI), which leads to the downregulation of RNase L activity (Martinand, 
Montavon et al. 1999).  
1.8 BTV interactions with the IFN pathway 
Most viruses will induce the IFN response to a greater or lesser extent during 
infection. BTV has been shown to be a strong inducer of type I IFN, possibly as a 
result of its dsRNA genome (Tytell, Lampson et al. 1967, Huismans 1969). IFN 
synthesis during BTV infection has been demonstrated both in vivo and in vitro. 
When primary embryonic murine cells were infected with BTV-10A, an attenuated 
American vaccine strain of BTV-10, IFN could be detected in cell supernatants by 5 
h p.i, and increased until 24 h p.i (Huismans 1969).When infecting other cell types, 
including human cells, similar results were obtained (Jameson and Grossberg 1981). 
However, it was found that field strains, including BTV-2, -4 and -6, induced higher 
amounts of IFN compared to the attenuated strain (Lyons, Schoub et al. 1982). Later 
studies also demonstrated that field strains of BTV were strong IFN inducers in vitro 
(Chauveau, Doceul et al. 2012). 
IFN synthesis in vivo was also demonstrated by intravenous injection of 4×108 PFU of 
purified BTV-10 V, a virulent strain derived from North America, into mice and IFN 
was assessed in blood samples collected at different time points. IFN was detected 
at 4 h p.i and reached its maximum concentration between 8 to 12 h p.i. Then the 
titer decreased and became undetectable at 24 h p.i (Huismans 1969). However, in 
another experiment, injection of 106.8 PFU of BTV into mice induced a rapid IFN 
production that reached a peak at 8 h p.i (Jameson, Schoenherr et al. 1978). 
Experiments have also been conducted in sheep and cattle, natural hosts of BTV. 
Infection in bovine foetuses with BTV-10 resulted in IFN detection in both serum and 
tissues (MacLachlan, Schore et al. 1984). On the other hand, when sheep were 
infected with BTV-10, -11, -13 or -17, IFN was detected in serum at 5 d.p.i, reaching 
a peak at 6 d.p.i (Foster, Luedke et al. 1991).  
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1.8.1 Induction of type I IFN by BTV 
PAMPs of BTV are the keys for the virus to induce host IFN response. As a dsRNA 
virus, the genome itself is a strong potential PAMP for the IFN response. It was shown 
that the injection of 10 ug of purified BTV-10A genomic dsRNA into mice induced IFN 
synthesis in vivo after 2 h, reaching a peak 6 h following injection (Eksteen and 
Huismans 2016). Further experiments showed that transfection of BTV dsRNA into 
cells also activated IFN-β (Vitour, Doceul et al. 2014). These data suggest that the 
BTV viral genome can act as PAMPs. However, later experiments revealed that UV-
inactivated BTV virus also induced IFN production both in vivo (mice) and in vitro 
(rabbit cells)(Jameson, Schoenherr et al. 1978, Taylor and O'Brien 1985). However, 
another study suggested that BTV-8 replication is a requirement for IFN-β 
expression, as in BTV-8 infected A549 cells and MDBK cells, the level of mRNA of IFN-
β increased synchronously with BTV viral RNA synthesis. On the contrary, the level 
of IFN-β mRNA in cells infected with UV-inactivated virus was close to background 
levels (Chauveau, Doceul et al. 2012). 
1.8.2 Modulation of the IFN pathway by BTV 
Previous data suggests that BTV-8 infection inhibits the IFN-β promoter activity after 
stimulation of the RIG-I-like pathway (Vitour, Dabo et al. 2009). The non-structural 
protein NS3 shows the strongest capability to inhibit IFN-β promoter activity. NS3 
from both field and attenuated strains of different serotypes induce a similar 
response. Furthermore, NS3 reduces the level of IFN-β mRNA, which indicates that 
transcription of IFN-β is also affected by the NS3 protein. However, NS3 does not 
affect the translation of in vitro transcribed mRNA, suggesting that NS3 may not play 
a role in regulating translation. Moreover, the CMV promoter is not affect by BTV 
NS3, indicating that NS3 may not inhibit a broad range of promoters (Chauveau, 
Doceul et al. 2013). 
NS4 is encoded by the alternative ORF in BTV segment 9 and is also reported to be 
an IFN antagonist (Ratinier, Shaw et al. 2016). Sheep endothelial cells infected with 
a BTV-8 NS4 deleted virus (BTV-8ΔNS4) released a much greater amount of IFN into 
the supernatant compared to wild-type BTV-8 (BTV-8wt) (Ratinier, Shaw et al. 
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2016). Moreover, the growth of BTV-8wt in IFN-competent cells is more efficient 
than BTV-8ΔNS4. These results suggest BTV-8 NS4 is a strong IFN antagonist that 
blocks IFN synthesis in host cells. However, RNAseq experiments revealed that cells 
infected with either BTV-8wt or BTV-8ΔNS4 infected cells both induced the 
transcription of ISGs. This indicates that although NS4 inhibits host IFN production 
to a certain extent, NS4 is not able to entirely shutdown the host immune response. 
Similarly, with BTV NS3, BTV-8 NS4 also inhibits IFN-β promoter activity, as well as 
ISRE promoter. As BTV-8 NS4 it localises to the nucleolus and has a putative nucleic 
acid binding domain at the C-terminal, it was suggested that BTV-8 NS4 may regulate 
host transcription.  
1.9 Aims 
AHSV and BTV are related members of the genus Orbivirus. These two viruses share 
a similar structure and viral protein functions. BTV NS4 has been shown to be an IFN 
antagonist and is a determinant of virulence. The presence of an AHSV NS4 has also 
been suggested and identified (Zwart, Potgieter et al. 2015). However, unlike BTV 
NS4 which is conserved across serotypes, AHSV NS4 is divided into two distinct groups 
and the amino acid sequences are much longer than that of BTV NS4. However, the 
functions of AHSV NS4 remain to be described.  
Reverse genetics systems are powerful tools for the study of viral proteins and virus 
replication. Reverse genetics systems for orbivirus are well developed (Boyce, Celma 
et al. 2008, Kaname, Celma et al. 2013, Van de Water, van Gennip et al. 2015). The 
goal of this project was to develop a reverse genetics system for AHSV and to study 
the function(s) of AHSV NS4 protein. During the course of this study, a reverse 
genetics system for AHSV was developed and published (Conradie, Stassen et al. 
2016).  
The specific aims of this project are the following: 
 To analyse the sequences of AHSV segment 9 and perform phylogenetic 
analysis of the AHSV NS4 protein. 
 To establish a reverse genetics system for AHSV in order to rescue wild type 
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and NS4 deletion mutants of AHSV. 
 To study the function(s) of the AHSV NS4 protein and characterise its role(s) 
in viral replication.  
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 Materials and Methods 
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 Materials and methods 
2.1 In silico analyses 
Bioinformatics analysis to identify ORFs in segment 9 of AHSV occurred on two 
separate occasions. The initial analysis was performed on 38 sequences downloaded 
from GenBank (as of July 2014). The second set of analysis were performed on 207 
AHSV sequences available in GenBank (as of August 2016) and included full genome 
sequences to allow reassortment/segment linking studies as well as to confirm the 
initial results. Bioinformatics analysis was carried out using CLC Genomics 
Workbench, Version 6.5. There are a number of programs in CLC Genomic Workbench 
(https://www.qiagenbioinformatics.com/). Initially, ORFs were identified and the 
NS4 coding sequences were extracted and aligned using ClustalW. Sequence motifs 
were examined using MOTIF SEARCH (http://www.genome.jp/tools/motif/) and 
NoD (http://www.compbio.dundee.ac.uk/www-nod/HelpDoc.jsp). 
Dr Joseph Hughes (CVR Bioinformatics Service) aligned each ORF using MAFFT 
(Katoh, Kuma et al. 2005). Duplicate and truncated sequences or sequences 
containing gaps or missing start codons were removed from the alignments. 
Selection of substitution model was performed using jModeltest (Posada 2008) and 
maximum likelihood phylogenies were reconstructed (1,000 bootstraps) using RAxML 
8.2.8 (Stamatakis 2014). 
2.2 Antibodies  
The primary antibodies used in immunofluorescence and western immunoblot were 
a rabbit anti AHSV NS4-I, a rabbit anti-NS4-II, a rabbit anti-AHSV VP7 antibody 
(Proteintech Group, Inc.) and rabbit anti-tubulin (Sigma T3320). Antibodies to detect 
the AHSV proteins had to be made commercially. Anti-NS4-I the antibody was raised 
against the entire sequence of NS4-I, anti-NS4-II was raised against the entire 
sequence of NS4-IIa and anti-AHSV VP7 was raised against the entire sequence of 
AHSV-1 VP7. The antigen was tagged with Glutathione S-transferase (GST) tag and 
expressed in bacteria (Proteintech Group, Inc.). Rabbits were immunized at least 4 
times prior to bleeding for sera collection. 
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The secondary antibodies used for immunofluorescence included: Alexa Fluor 594 
goat anti-rabbit (Life Technologies, A11037) and Alexa Fluor 488 goat anti mouse 
(Life Technologies, A21202). The secondary antibody used for western immunoblots 
was a donkey anti-rabbit HRP conjugate (GE, GENA9340V). 
2.3 Cell lines 
BSR cells, derived from the baby hamster kidney cell line BHK-21 (kindly provided 
by Dr. Conzelmann), were cultured in Dulbecco’s Modified Eagle’s Medium (DMEM, 
Gibco) supplemented with 5% foetal bovine serum (FBS) (Life Technologies). E. Derm 
cells, a fibroblast cell line obtained from dermis of a four-year-old female horse 
(ATCC number CCL-57), were kindly provided by Dr. Murcia (CVR, UK). E. Derm cells 
were grown in DMEM supplemented with 15% FBS and 1% MEM non-essential amino 
acids (Invitrogen). A549 cells (Dr Elliott, CVR), a human alveolar basal epithelial cell 
line derived from andenocarcinoma, were grown in DMEM supplemented with 10% 
FBS. A549-NPro a cell line derived from human A549 cells that constitutively 
expresses the bovine viral diarrhoea virus NPro (a gift from Dr Randall, University of 
St Andrew’s, UK) were grown in DMEM supplemented with 10% FBS and 2 ug/ul 
puromycin. HEK-293T cells were cultured in DMEM supplemented with 10% FBS. CPT-
Tert cells (kindly provided by David Griffiths) are sheep choroid plexus cells 
immortalized with the simian virus 40 (SV40) T antigen and human telomerase 
reverse transcriptase (hTERT). The cells were grown in Iscove's modified Dulbecco's 
medium (IMDM), supplemented with 10% FBS (Arnaud, Black et al. 2010). All 
mammalian cells were grown at 37 ℃ in a 5% CO2 humidified atmosphere.  
Kc, a cell line derived from larvae of Culicoides sonorensis larvae (Wechsler, 
McHolland et al. 1991) were grown in Schneider's Drosophila Medium supplemented 
with 15% FBS and incubated at 28 ℃. 
Cells were grown to confluency in a 75-150 cm2 flask, washed with PBS, trypsinised 
with ATV and resuspended in the appropriate media supplemented serum as 
previously described above. Cells seeded to the appropriated density to reach 50% 
to 80% confluence the following day (i.e., a 12-well plate was seeded with 1×105 BSR 
cells for transfections to rescue virus by reverse genetic). Cells were seeded onto 13 
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mm circular coverslips (Cover glass Thickness No. 0, VWR) if the transfected samples 
were to be used for immunofluorescence and confocal microscopy. Prior to use, 
cover slip were sterilised by soaking in 75% (v/v) ethanol (Sigma) for a minimum of 
30 min. Coverslips were then air dried in the MSC hood and placed into each well of 
the respective plate. 
2.3.1 Generation of equine primary cells  
Horse aorta endothelial primary cells were isolated from horse aortas supplied by 
Mr. Richard Irvine (post-mortem department, University of Glasgow, UK). Batch 1 
and batch 3 primary cells were from the aortas of 1-year-old female horses. The 
aortas were prepared by removing the connective and adipose tissue on the external 
side of the aortas. The cleaned aortas were washed with PBS containing 1% (v/v) 
penicillin-streptomycin (Invitrogen). Aortas were cut into ~5 cm×5 cm pieces and 1 
ml of 2 mg/ml collagenase (Sigma) diluted in FBS-free DMEM was added to the 
endothelial side of the aorta. The aorta and collagenase were incubated for 1 h at 
37 ℃. The cells that had been incubating with the collagenase were then scraped 
from the surface and transferred into fresh media. The harvested cells were gently 
centrifuged and resuspended in human large vessel endothelial cells basal medium 
(Cell Work) supplemented with 15% FBS, 1% Penicillin-Streptomycin, 100 U/ml 
Nystatin (Sigma), 2% Large Vessel Endothelial Cell Growth Supplement (Cell Work) 
and 0.1% Amphotericin B/Gentamycin (Cell Work). Cells were placed into a 12 well-
plate and grown in a low oxygen environment. (3% oxygen, 5% CO2, 37 ℃ humidified 
atmosphere). 
2.3.2 Screening of cell lines for pestiviruses and mycoplasma 
All the cell lines were routinely screened for mycoplasma and pestivurses 
contamination by Aislynn Taggart using commercial available kits. 
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2.4 Viruses 
The nine AHSV reference strains (AHSV-1 to AHSV-9) were obtained from the Istituto 
Zooprofilattico Sperimentale dell'Abruzzo e del Molise "Giuseppe Caporale" (Teramo, 
Italy). Encephalomyocarditis virus (EMCV) was kindly provided by Dr. Randall 
(University of St Andrew’s, UK). 
2.5 Preparation of virus stocks 
Rescued viruses were passaged twice after rescue to generate stocks for subsequent 
experiments. From rescue (p0) in a 6-well plate, 100 ul of the supernatant was used 
to infect BSR cells were seeded in a T25cm2 flask to generate a p1 stock. The virus 
inoculum was left on the cells until visible CPE. Care was taken to ensure the medium 
did not acidify. The supernatant was harvested and cell debris pelleted by 
centrifugation. The passaged virus was stored at 4 ℃ while an aliquot was stored at 
-80 ℃. The cell pellet was kept to purify the dsRNA as described in section 2.21. To 
generate a p2 stock, 200-300 ul of the p1 stock was used to infect a T225cm flask. 
As for the p1 stock, cells incubated until visible CPE. The supernatant was harvested 
and cell debris pelleted by centrifugation. The passaged virus was stored at 4 ℃ and 
an aliquot was stored at -80 ℃. 
2.6 Virus Quantification 
The cell-free virus stocks were quantified using plaque assays and end-point dilutions 
(TCID50/ml) in BSR cells. 
2.6.1 Plaque Assay 
Plaque assay is a method to calculate a virus titre based on the number of plaque 
forming units (PFU) in a standard cell culture system. It relies on the ability of the 
virus to induce visible CPE (cell death) that leaves holes in the monolayer. We 
titrated the viruses in BSR cells since Kc, E. Derm and primary horse aorta 
endothelial cells were not amenable to the formation of plaques. Ten-fold serial 
dilution of the viruses were made in DMEM without supplements and 500 ul of virus 
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dilutions were added to a 80% confluent monolayer of BSR cells and incubated for 
1.5 h at 37 ℃ in a humidified 5% CO2 environment. Afterwards, the inoculum was 
aspirated, the cells washed and overlayed with 1.5% low melting point agarose in 
MEM supplement 4% FCS. Cells were incubated at 37 ℃ in a humidified 5% CO2 
environment for 72 h when they were fixed with 4% formaldehyde. Plaque overlay 
was removed and the monolayer stained with 1.5% crystal violet and the plaques 
counted. Plaque assays were performed in duplicate. Virus titre was calculated as 
the number of PFU/ml. 
2.6.2 Endpoint dilution assay  
Tissue culture infectious dose (TCID50) is an endpoint dilution assay that allows virus 
quantification based on the dilution that has less than 50% CPE in the cell monolayer. 
Ten-fold serial dilution of each virus was made in quadruples in a 96-well plate. One 
hundred ul of 1×104 BSR cells were then added to each well. Plates were incubated 
for 96 h and the presence of CPE in each well was scored using a light microscope. 
Viral titers were calculated by the method of Spearman and Karber and expressed 
as log10 TCID50/ml.  
2.7 Virus growth curves.  
BSR, E. Derm, Kc and primary horse aorta endothelial cells were seeded in 12-well 
plates and infected by the indicated viruses at a MOI of 0.01 (BSR, E. Derm and Kc 
cells) or 0.1 (primary horse aorta endothelial cells). The MOI used for E. Derm, Kc 
and primary horse aorta endothelial cells was based on virus titers in BSR cells. The 
virus inoculum was incubated with the cells for 1.5 h at 37 ℃ in a 5% CO2 
environment and then aspirated and washed in medium. Fresh medium was added 
to the cells and cell culture supernatants were collected at 12, 24, 48 and 72 h post 
infection (p.i.). The virus titer (expressed as TCID50/ml) was determined by endpoint 
dilution as described in section 2.6.  
Virus growth was assessed in cells in the presence of 1,000 U of universal type I 
interferon. Universal type I Interferon (uIFN) was obtained from PBL 
InterferonSource. E. Derm cells were treated with 1,000 U of uIFN 4 h prior infection 
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with AHSV at an MOI equivalent of 0.01. One and half-hours after infection, the virus 
was aspirated, cells washed with once with medium and fresh medium without uIFN. 
Cell supernatants were collected at 12, 24, 48 and 72 h post-infection and virus 
infectivity was subsequently estimated by endpoint dilution analysis on BSR cells 
(see section 2.6).  
Virus growth in interferon competent primary horse aorta endothelial cells in the 
presence of ruxolitinib (rux), an inhibitor of the IFN pathway, was also assessed. Rux 
was obtained from Selleckchem and diluted in DMSO. For comparative purposes, 
DMSO was added to the control infected cell at same final concentration as rux-
treated cells to ensure the effect was not due to the DMSO. Horse aorta endothelial 
cells were treated with rux or DMSO for 4 h prior to infection with AHSV at a MOI 
equivalent of 0.1 for 1.5 h at 37 ℃. Rux or DMSO was added to the medium during 
infection. Afterwards, the inoculum was aspirated, cells were washed with medium 
and fresh medium containing either rux or DMSO was added. Supernatants were 
collected at 12, 24, 48, 72 and 96 h post-infection and virus infectivity was 
subsequently titrated by endpoint dilution analysis on BSR cells (see section 2.6). 
2.8 Commercial plasmids 
The construction of the plasmids to generate the T7 ssRNA for the reverse genetic 
system for AHSV was based on the design used for BTV (Boyce, Celma et al. 2008, 
Ratinier, Caporale et al. 2011). An exact copy of each segment of AHSV-4 (GenBank 
accession numbers JQ796724–JQ796733) and segment 9 for AHSV-1, AHSV-6 and 
AHSV-7 (GenBank accession numbers AM883170, AHU33000 and JQ742012) were 
commercially synthesised (Genscript). The T7 sequence was placed at the 5’ end 
such that it allowed the start of the transcript at the first G of all the AHSV segments. 
To ensure that the transcript finished at the last C of the segments, a unique 
restriction site was incorporated. The restriction sites were Bbs1 (Segment 1), Bsa1 
(Segments 2, 3, 5, 6, 8, 9 and 10) and Sap1 (Segments 4 and 7).  
pCI plasmids that contained the alternative ORF of segment 9s of AHSV-1, AHSV-4, 
AHSV-6 or AHSv-7 were commercially synthesised (Genscript. GenBank accession 
numbers are the same as above). pCI vector was from Promega. pCI BTV-10 NS2 
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(GenBank accession number NC_006007) and pCI BTV-8 NS4 (GenBank accession 
number JX680455) have been previously described (Stewart, Hardy et al. 2015, 
Ratinier, Shaw et al. 2016). 
Mutant segment 9s of AHSV-1, AHSV-4, AHSV-6 and AHSV-7 were commercially 
synthesised to delete NS4 ORF, the putative methionine initiation codons of NS4 
were removed and several stop codons were added. None of the introduced 
mutations changed the amino acid (AA) residue in the VP6 ORF. For AHSV-1 
mutations included: G209A, T305C, G413A, T449C, T452C and G569A. For AHSV-4 
mutations included: T215C, T260C, T296C, T395C and C491G. For AHSV-6 mutations 
included: T149C, G209A, T305C, T401C and T470A. For AHSV-7 mutations included: 
T149C, T179C, G209A, T305C, T377C, G413A and T470A. We also replaced bases in 
AHSV-7 segment 9 including T149C and T179C to express an AHSV-1 NS4-like protein 
and C577T to express AHSV-6 NS4-like protein. However, in order to express AHSV-6 
like-NS4 protein, an amino acid residue in the AHSV-7 VP6 ORF, tyrosine at position 
187, had to be replaced to isoleucine. 
 
2.9 Plasmid transformation and purification 
All plasmids were transformed into either XL-1blue (Agilent) or Stbl2 (Invitrogen) 
chemically competent E.coli as per manufacturer’s protocol. After transformation 
XL-1 Blue-transformed cells were grown at 37 ℃ while Stbl2 at 30 ℃. 
Plasmids were extracted from transformed E.coli using an alkaline lysis-based 
extraction with a QIAgen kit according to manufacturer’s protocols.  
2.9.1 Polymerase chain reaction  
Amplification of NS4-I was performed for cloning into pCI empty. Primers were 
designed flanked with restriction endonuclease sites to allow ligation into the vector 
(Table 2-1). The PCR reaction mix consisted of 1 x PfuUltra II Reaction Buffer (final 
concentration of 2 mM MgCl2), 0.25 mM dNTPs, 20 pmol of each primer, 1ul of 
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PfuUltra II fusion HS DNA polymerase, between 50–250 ng of vector and made to a 
final volume of 25 ul with ultrapure water. Cycle condition consisted of an initial 
denaturation of 95 ℃ for 3 min, followed by 40 cycles of 95 ℃ for 20 s, 55–60 ℃ for 
20 s, 72 ℃ for 30 s and a final extension at 72 ℃ for 3–5 mins. For annealing 
temperatures, please see Table 2-1. 
Table 2-1 PCR primers used for the amplification of NS4. The restriction endonuclease site is 
highlighted in red. The position in the segment is given. 
Primer 
Name 
Sequence (5’ – 3’) Position in the 
genome 
(5’–3’) 
Tm 
NS4-IF TAT CTCGAG 
CGGAAAAGGGTGAGGAAAAG 
184–203 53.7/61.5 
NS4-IR TGT GTCGAC 
AACTCCAACCTTCTTTCTGAC 
692–672 52.5/61.6 
2.10 Agarose electrophoresis 
Agarose gel electrophoresis was performed on horizontal gels consisting of 1.0% or 
1.5% (w/v) agarose (Invitrogen), TAE buffer (40 mM Tris-HCl; 20 mM glacial acetic 
acid; 2 mM EDTA; pH 7.0) and 1 x SybrSafe (Invitrogen). PCR products, DNA and 
dsRNA samples were loaded into the agarose gel in 6× loading dyes and 
electrophoresed in TAE buffer. DNA and PCR products were run for 30–60 min at 90–
110 V in a Minisub DNA cell (BioRad). dsRNA samples were run at 4℃ for either 4 h 
at 90–110 V or 30 V overnight in a Minisub DNA cell (BioRad). The size of the bands 
was determined by comparison with a 1 Kb plus molecular weight marker 
(Invitrogen). Gels were visualised by UV illumination at 260 nm. 
2.11 Generation of pCI expression constructs 
The pCI vector was to express viral proteins in mammalian cells. Vectors that 
expressed NS4-I alone and either AHSV VP1, VP3, VP4, VP6, VP7, NS1 or NS2 for the 
first round of transfections for AHSV rescue were required.  
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2.11.1 Preparation of vector and inserts 
Empty pCI (pCI.empty) and pUC57AHSVS1, pUC57AHSVS3, pUC57AHSVS4, 
pUC57AHSVS5, pUC57AHSVS7, pUC57AHSVS8 and pUC57AHSVS9 were cut with EcoR1 
and Sal1 to either linearize the vector or ligate an insert that contained the complete 
segment. The reaction conditions consisted of 1 x Cutsmart buffer (NEB), 100 U 
EcoR1 (NEB), 100 U Sal1 (NEB) and 100 ug of plasmid. The samples were incubated 
at 37 ℃ for 1 h and run on a 1% agarose gel in TAE buffer. 
2.11.2 Gel purification of vector and insert 
The DNA bands of the correct size were excised from the agarose gels using a sterile 
scalpel blade and the DNA extracted using the QIAquick Gel Extraction Kit (QIAGEN). 
The quantity of the DNA was measured using a NanoDrop (Thermo). 
2.11.3 Ligation 
Restriction digested PCR-generated products and full-length AHSV segments 
digested from the pUC57 vector were directly ligated into the prepared linear pCI 
vector with compatible ends. Ligation reactions were performed using the Rapid DNA 
ligation kit (Roche) using vector to insert molar ratios of 1:5 or 1:10 and incubated 
at room temperature overnight.  
2.12 Mutagenesis of the NS4 coding sequence in segment 9 
Mutations were made in either the coding regions of NS4-II or  to identify the 
determinants of protein shutdown. Mutations were introduced in a pCI plasmid 
expressing wild type AHSV NS4 gene by site-directed mutagenesis (Table 2-2). Sets 
of overlapping or complementary primers were designed that would allow the 
introduction of the mutations into segment 9 to stop expression of NS4 (See Table 
X). The mutagenesis reaction consisted of 1 x reaction buffer, 15 pmol of each 
primer, 0.2 mM dNTP, 2.5 U PfuUltra HF DNA polymerase and 50–100 ng of plasmid 
DNA. To ensure that no other mutations were introduced the number of cycles was 
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kept to a minimum. The reaction conditions were as follows: one cycle at 95 ℃ for 
30 s followed by 15 cycles at 95 ℃ for 30 s, 55 ℃ for 1 min and 68 ℃ for 4 min.  
The parental DNA plasmid was then digested with Dpn1, which only recognises 
methylated DNA rather than DNA generated by PCR. Chemically competent XL-1Blue 
E.coli was transformed with 1 ul of the Dpn1-treated samples according to section 
0.  
Table 2-2. Primers used to truncate NS4-II and  to ensure that they only express the conserved 
core/central domain of NS4-II 
Mutation  Primer Pair TM 
N-terminal 
deletion of 
NS4-II 
F-CGAGAATTCAGGCTGGGGAGAAGAAGAACAAG 
R-CTTGTTCTTCTTCTCCCCAGACTGAATTCTCG 
69.5 
69.5 
C-terminal 
deletion of 
NS4-II 
F-GAACCATTGGATAGGATAGGCGGCTGCAGC 
R-GCTGCAGCCGCCTATCCTATCCAATGGTTC 
70.9 
70.9 
 
2.13 Quantification of nucleic acids 
The concentration of DNA, ssRNA, dsRNA samples were measured in Nanodrop 2000 
(Thermo Fisher).  
Qualification of ssRNA samples (described in section 2.18) transcription was tested 
in Agilent 2100 Bioanalyzer with chip supplied. Gel and RNA dye were equilibrated 
in room temperature and mixed well, and were loaded into the chip by plunger 
supplied. Then load another 9 ul of gel into each well of the chip. The dsRNA samples 
were diluted ~1 ng/ul. 5 ul of the RNA ladder and 9 ul of dsRNA samples were loaded 
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in each well. The chip was vortexed for 1 min at 2,400 rpm then analysed by an 
Agilent 2100 Bioanalyzer following manufacturer’s instructions. 
2.13.1 Sequence analyses 
The sequencing of DNA (PCR products or/and plasmid constructs) was outsourced to 
Source Bioscience. The chromatograms were analysed using CLC Genomics 
Workbench. Miscalled bases were corrected, the ends trimmed and the sequence 
aligned to reference sequence. The samples were occasionally subjected to blastn 
on the NCBI website (https://blast.ncbi.nlm.nih.gov/). All edited sequences were 
analysed using the following programmes: BlastN v2.0 to 2.29 and BlastP v2.0 to 
2.2.9 (Altschul, Gish et al. 1990, Gish 1993, Madden, Tatusov et al. 1996, Altschul, 
Madden et al. 1997, Zhang and Madden 1997, Zhang, Schwartz et al. 2000, Morgulis, 
Coulouris et al. 2008, Camacho, Coulouris et al. 2009, Boratyn, Schäffer et al. 2012), 
Translate (CGC Accerlrys, Inc.), Flip ORF (FLIP: a Unix C program) and Frames (CGC 
Accerlrys, Inc).  
2.14 Transfections 
Lipofectamine2000 (Invitrogen), a lipid-based reagent, was used to facilitate the 
transfection of recombinant plasmids and ssRNA into the different eukaryotic cell 
types.  
A lipid:DNA complex was prepared on the day of transfection by adding 2.5 µl of 
Lipofectamine Transfection Reagent to 1µg of DNA or ssRNA in optimum media 
following the manufacturer’s instructions. Prior to transfection the cells were 
washed in the appropriate media, the lipofectamine:nucleic acid mix was added 
drop-wise and incubated at 37 ℃ in a 5% CO2-in-air atmosphere for 2–6 h when the 
media was replaced and the cells were placed at 37℃ in a 5% CO2-in-air atmosphere. 
2.15 Luciferase assays 
We established a luciferase reporter system to measure the influence of AHSV NS4 
on host cell protein synthesis using the change of Firefly luciferase (Fluc) as an 
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indicator of protein regulation. CPT-Tert cells were co-transfected (see section 2.14) 
with a 100 ng pGL3Flu, a CMV-driven expression plasmid which expressed firefly 
luciferase, and 100 ng of pCI expression plasmids for either AHSV NS4-I, NS4-IIα, β 
or γ or BTV NS4 or BTV NS2 and 300 ng of pCI.empty to normalise the DNA amounts. 
As a control, 400 ng of pCI.empty were co-transfected with pGL3Fluc. Twenty-two 
hours post-transfection the cell culture supernatant was aspirated and 100 ul of 
passive lysis buffer (Promega) was added. Cell monolayers and lysis buffer were 
incubated at room temperature 15 min on an orbital shaker. The sample was 
harvested, centrifuged to pellet cellular debris and the supernatant used to assess 
luciferase activity. Five microliters of the supernatant were added to 50 ul of LARII 
(Promega), mixed and read immediately on a GLOMAX luminometer (Promega). Data 
is expressed as relative light units (RLU). 
2.16 Apoptosis assay (caspase 3/7 pathway) 
To determine if NS4 had a role in inducing apoptosis, we measured the activation of 
caspase3/7 in transfected cells using the Caspase-Glo 3/7 Assay Systems (Promega). 
Briefly, cells were transfected as in section 2.14 with the slight modification that 
the pGL3.CMVFluc plasmid was omitted. In particular, cells were grown in 96-well 
plates, transfected with 6.67 ng of the vector of interest and 26.67 ng of control pCI 
or 33.33 ng of pCI-empty. At 3, 6, 9, 12, 15 and 22 h post-transfection the media 
was aspirated and cells lysed with Passive Lysis Buffer (Promega). After 15 mins, 5 
ul of the cell lysate was added to 50 ul of the Caspase-Glo® 3/7 Substrate and 
incubated at room temprature for of 1 h. The substrate is Caspase-3/7 DEVD-
aminoluciferin that is cleaved if active caspase 3 or 7 is present in the substrate and 
results in a proluminescent that can be measured. The samples were measured using 
a Promega GLOMAX luminometer. 
2.17 Immunofluorescence and confocal microscopy.  
Immunofluorescence followed by confocal microscopy was performed on infected 
and transfected cells to examine the localisation of NS4 and monitor virus 
replication. Cells were seeded onto coverslips as described in section 2.14. BSR cells 
were either transfected as in section 2.14 with 100 ng of the indicated NS4 
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expression plasmid (NS4-I, NS4-II,  or ) or infected with the indicated viruses at 
an MOI of 0.1. Cells were fixed with 4% formaldehyde for 20-30 min. 24 h post-
transfection or infection. 
Cells were permeabilized with 1% (v/v) Triton X100 in PBS for 15 mins, blocked in 
0.4% fish gelatine, in PBST (PBS and 0.1% Tween 20) for 10 min followed by a second 
block in 2.5% goat sera in PBST for 10 min. These steps were performed at room 
temperature on an orbital shaker. The primary antibody was diluted in 2.5% goat 
sera in PBST and samples were incubated overnight at 4 ℃ on an orbital shaker. 
Secondary antibodies conjugated with either Alexa Fluor 488 (Invitrogen, Molecular 
Probes) or Alexa Fluor 594 (Invitrogen, Molecular Probes) were diluted in 2.5% goat 
sera in PBST and incubated for 1 h at room temperature in a dark environment. The 
sample was washed 5 times in PBST and once in PBS. Slides were mounted using 
VECTASHIELD Mounting Medium with DAPI (4′, 6-diamidino-2-phenylindole, Vector 
Laboratories). Slides were analysed using a Leica GMIR2 confocal microscope. 
2.18 Western blotting.  
Expression of viral and cellular proteins was monitored by western immunoblot. 
Briefly, cells were lysed with Laemmli Buffer and proteins separated in pre-cast 4%-
12% Tris-gel (NuPage, Thermo) in MES buffer at 200 V for 60 min. Proteins were 
transferred to a 0.45 µm nitrocellulose membrane (Thermo) or PDVF (Amersham/GE 
Healthcare) using a mini Trans-Blot apparatus (BioRad) in ice-cold transfer buffer 
(25 mM Tris, 192 mM glycine, 20% [v/v] methanol). Transfer was performed at at 150 
V for 30 min at room temperature for each apparatus, respectively.  
The membranes were blocked in 5% skimmed milk in PBST for a minimum of 1 h at 
room temperature on an orbital shaker. Primary antibodies were diluted in 5% 
skimmed milk in PBST and incubated at 4 ℃ overnight on an orbital shaker. 
Membranes were washed 5 times in excess PBST and peroxidase-labelled secondary 
antibodies were added and incubated for 1 h at room temperate. The signal was 
visualised using a ChemiDoc XRS+ scanner (Biorad). 
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2.19 In vitro transcription 
Plasmids containing the AHSV genome segments were linearized at the last 
nucleotide of the 3’UTR of the segment (see section 2.11 for specific restriction 
endonuclease) using restriction enzymes. Linearized plasmids were purified using 
phenol-chloroform.  
Linearized plasmids were used as template of in vitro transcription using mMESSAGE 
mMACHINE T7 ultra kit (Ambion) as per manufacturer’s protocol. The ARCA-capped 
ssRNAs were then extracted by phenol-chloroform extraction and then excess dNTPs 
and ARCA cap were removed from the ssRNA by size exclusion through Illustra 
Micropin G25 columns (GE Healthcare). The quality of the RNA was assessed by 
electrophoresis analysis (as described in section 2.10) and Bioanalyzer (Agilent). 
2.20 Rescue of AHSV-4 and AHSV reassortants 
AHSV-4 and reassortants containing segment 9 (S9) from different strains of AHSV 
and the backbone of AHSV-4 were rescued by reverse genetics as previously 
described for BTV and AHSV (Boyce, Celma et al. 2008, Matsuo, Celma et al. 2010, 
Ratinier, Caporale et al. 2011, Van Rijn, Van de Water et al. 2016). BSR cells at a 
confluency of 70% to 90% were co-transfected with lipofectamine 2000 as described 
in section 2.14 with 150 ng of each of the six mammalian expression plasmids for 
AHSV segments 1, 3, 4, 5, 8 and 9. At 18h post-transfection, cells were co-
transfected again with 1×1011 molecules of each of the 10 AHSV ssRNA segments 
made in vitro. Three to four h post-transfection, the medium was replaced with 
fresh DMEM containing 5% FBS. Cells were monitored daily and supernatants were 
collected when CPE was evident.  
The reference strain of AHSV-4 (GenBank accession numbers JQ796724–JQ796733) 
was used as a parental virus for the segment 9 reassortants described below. The S9 
of the reference strain of AHSV-4 encodes an NS4 “type I” (NS4-I) and therefore, the 
resultant virus is referred to as AHSV NS4-I. Three additional reassortants were also 
rescued that contain nine genomic segments (the “backbone”) of the AHSV-4 
reference strain and S9 derived from three different viral strains and are referred 
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to as: AHSV NS4-II, AHSVNS4-II and AHSV4NS4-II. NS4-deletion mutants are 
referred to as AHSV4NS4-I, AHSV4NS4-II, AHSV4NS4-II and AHSV4NS4-II. 
2.21 dsRNA extraction  
dsRNA was extracted from infected cell as already described (Boyce and Roy 2007). 
Infected cell pellets (either BSR, Kc, E. Derm or horse aorta endothelial cells) were 
resuspended in Trizol (Invitrogen) and processed according the manufacturer’s 
protocol. Lithium chloride was added to the total RNA to a final concertation of 2 M 
and incubated overnight at 4 ℃ to precipitate ssRNA. Viral dsRNA was precipitated 
using 100% isopropanol in the presence of sodium acetate, washed twice in 70% (v/v) 
ethanol and resuspended in RNase free water. 
2.22 RT-PCR of AHSV segment 9 
All reactions were performed using the SuperScript III reverse transcription kit (Life 
Technologies) according to the manufacturer’s protocol. The RT step was performed 
using AHSV segment 9 UTR specific primers (Table 2-3). Each reaction consisted of 
1 x FS RT Buffer, 1 mM of each dNTP, 18–25 mol of primer, 200 U of SuperScript® 
III RT, 10 mM DDT, 40 U of RNaseOUT and ~1 µg of dsRNA. Each RT reaction was 
performed in duplicate. In one reaction, SuperScript® III RT was eliminated to 
determine whether there was DNA contamination of the RNA samples. The RT 
reaction conditions were slightly modified from the manufacturer’s recommendation 
to include a step to denature the dsRNA. The conditions were as follows: the dRNA, 
primers and dNTPs were heated on ice 95 ℃ for 5 min and placed on ice for 2–3 min. 
The first strand buffer, enzyme and RNAse inhibitor were added and the reaction 
incubated at 50 ℃ for 1 h, the RT enzyme was denatured at 85 ℃ for 15 min and the 
reaction was placed at 4 ℃ or at -80 ℃ until the PCR reaction was performed. 
The PCR reaction mix consisted of 1 x PfuUltra II Reaction Buffer (final concentration 
of 2 mM MgCl2), 0.25 mM dNTPs, 20 pmol of each primer, 1ul of PfuUltra II fusion HS 
DNA polymerase and 50–250 ng of vector. Cycle conditions consisted of an initial 
denaturation of 95 ℃ for 3 min, followed by 40 cycles of 95 ℃ for 20 s, 55 ℃ for 20s 
and 72 ℃ for 30 s and a final extension at 72 ℃ for 3–5 mins. 
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Table 2-3 Primers for the RT and PCR amplification of AHSV segment 9.  
Primer Name Sequence (5’ – 3’)  Tm 
As9_RT_Seq_F GTTGTCTCATGTCTTCGGC  53.6 
As9_RT_Seq_R CGTTTACCCCTGGACC  52.3 
 
2.23 Antiviral cytokines protection assays 
To determine whether AHSV infection of primary cell stimulated the production of 
IFN, the amount of IFN present in the media of infected cells was estimated using 
an IFN protection assay. Primary horse aorta endothelial cells were infected with an 
MOI equivalent of 2 for 1.5 h after which cells were washed twice in warm medium 
and fresh medium added. The supernatants were harvested 16 h post infection and 
stored at -80 ℃. Live viruses were inactivated by UV light exposure (20 mins). One 
hundred microliters of two-fold serial dilutions of UV-treated primary horse aorta 
endothelial supernatants were added to CPT-Tert cells (an indicator cells line for 
equine IFN) and incubated for 24 h at 37 ℃ in a 5% CO2 humidified environment. The 
culture medium was aspirated and cells infected with EMCV. Cells were monitored 
for CPE for 48–72 h. The cells were then fixed in 4% formaldehyde and stained with 
0.15% crystal violet to assess the integrity of the monolayer. A well was considered 
protected if greater than 75% of the monolayer was intact. As a control, 
commercially available equine interferon (eIFN, obtained from Kingisher Biotech) 
was used and as a calibrator, CPT-Tert cells were treated with 100 pg/ul of eIFN 
which was also two-fold serially diluted and infected with EMCV.  
2.24 In vivo pathogenicity studies 
All animal experimental procedures carried out in this study were approved by the 
ethical committee of the Istituto Zooprofilattico Sperimentale dell'Abruzzo e Molise 
“G. Caporale” (Teramo, Italy) (protocol no. 14040/2012) and further approved by 
the Italian Ministry of Health (Ministero della Salute) in accordance with Council 
Directive 131 86/609/EEC of the European Union and the Italian D.Igs 116/92. Animal 
 74 
 
experiments were performed as previously described (Ratinier, Caporale et al. 
2011). Litters of 4-day-old Swiss-NIH mice were infected intracranially with either 
200 PFU of the indicated virus or mock-infected with cell culture media. Mice were 
examined for clinical signs daily until the experiment was terminated 14 days p.i. 
Survival plots were constructed using data collected from 9 experimental groups (n 
= 11–16 per each group). 
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 Identification of the AHSV NS4 protein  
3.1 Introduction 
In the last few years, a body of evidence has accumulated on the roles that “small” 
ORFs play in key biological processes in various genomes from viruses and bacteria 
to vertebrates and humans (Bazzini, Johnstone et al. 2014, Storz, Wolf et al. 2014) 
(Jaber and Yuan 2013, Slavoff, Mitchell et al. 2013). It is also reported that 
mitochondria in eukaryotes also contain overlapping ORFs (Clayton 1984, Fearnley 
and Walker 1986). For viruses, overlapping ORFs are a common feature and are 
assumed to be a strategy for viral genome compression, which allows the viruses to 
increase the potential protein repertoire without enlarging their genome size 
(Chirico, Vianelli et al. 2010). For example, in hepatitis B virus, a dsDNA virus within 
the Hepadnaviridae, over 63% of the length of the viral polymerase ORF harbours 
alternative overlapping ORFs (Miller, Kaneko et al. 1989). Overlapping ORFs are also 
found in RNA viruses such as in influenza A virus, whose genome is composed of 8 
ssRNA segments and overlapping ORFs are found in segment 2 (Wise, Foeglein et al. 
2009). Overlapping ORFs may originate in different ways, including loss of the 
initiation or stop codons and thus extending the ORF into contiguous areas 
downstream of upstream of the gene. Alternatively, point mutations inside or 
outside the original ORF may generate novel initiation or stop codons inside or 
outside the original ORF (Krakauer 2000). Viruses mutate very rapidly providing 
plenty opportunities for the generation of overlapping ORF that in turn can provide 
potential benefits to virus replication and/or in counteracting the in viral genome 
transcription and translation regulation and give advantages in virus 
evolution(Johnson and Chisholm 2004, Saha, Podder et al. 2016).  
Viruses within the genus Orbivirus, including BTV, AHSV, GIV (Great Island virus) and 
EEV (Equine encephalosis virus) are composed of 10 segments of linear dsRNA. Until 
recently, it was thought that the 10 segments of dsRNA genome of the orbiviruses 
BTV and AHSV were monocistronic and encoded 7 structural, VP1 to VP7, and 3 non-
structural proteins, NS1 to NS3 (Sangar and Mertens 1983, Mertens, Brown et al. 
1984). These proteins were identified in BTV-infected cells or transfection of viral 
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genome RNA. However, older studies reported that when the BTV genome was 
translated in vitro, some unknown small translation products were observed, but 
these were believed by-products of the in vitro translation assays (Sangar and 
Mertens 1983). 
However, in 2008 in silico analysis of BTV and other orbiviruses indicated a putative 
short overlapping ORF of 77-79 amino acid residues in segment 9 of the genome 
(Firth 2008). Bioinformatics analysis indicated that this small ORF had a strong Kozak 
sequence in every strain identified and the amino acid sequence was conserved. 
Other orbiviruses, including AHSV, GIV, PALV (Palyam virus) and YUOV (Yunnan 
orbivirus) were also shown to contain a similar small ORF encoding 83 to 169 amino 
acid residues. This protein was named NS4. 
The BTV and GIV NS4 were shown (Belhouchet, Jaafar et al. 2011) to localise to the 
nucleoli in BSR cells (Belhouchet, Jaafar et al. 2011, Ratinier, Caporale et al. 2011). 
In addition, they possess dsRNA and dsDNA binding activities. The BTV NS4 protein 
was also shown (Belhouchet, Jaafar et al. 2011, Ratinier, Caporale et al. 2011, 
Ratinier, Shaw et al. 2016) to repress host cell protein synthesis and act as an 
interferon antagonist (Ratinier, Caporale et al. 2011, Ratinier, Shaw et al. 2016). In 
vivo experiments also showed that BTV NS4 is a determinant of virulence (Ratinier, 
Shaw et al. 2016). During the course of this PhD, a preliminary study focusing on the 
AHSV NS4 was published (Zwart, Potgieter et al. 2015). AHSV NS4 was found to be 
expressed in virus-infected cells (Zwart, Potgieter et al. 2015) and suggested that 
AHSV NS4 also localised to the nucleolus and possessed dsDNA (but not dsRNA) 
binding activity (Zwart, Potgieter et al. 2015). However, the function(s) of the AHSV 
NS4 were not explored.  
In this chapter, we aim to confirm published data on AHSV NS4 and begin to 
understand some of the biological properties of this protein. In particular, we will:  
a. Confirm and identify the presence of the NS4 ORF in AHSV segment 9 using 
bioinformatics approaches. 
b. Confirm the expression and localisation of the AHSV NS4 in transfected an 
infected cells. 
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c. Investigate the effects of the AHSV NS4 protein on cell protein expression 
and apoptosis. 
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3.2 Results 
3.2.1 Identification of alternative ORFs in AHSV segment 9 
Our initial in silico analysis of 38 available sequences from GenBank (24/07/2014) 
confirmed a previous study (Zwart, Potgieter et al. 2015) showing that the AHSV 
segment 9 contained an extra ORF with respect to the ORF expressing the minor 
structural and helicase protein, VP6. All of these sequences were analysed to predict 
the +1 ORF within the sequences. 
Similar to previous observations (Zwart, Potgieter et al. 2015), AHSV NS4 could be 
split phylogenetically into two separate clades, NS4-I and NS4-II (Figure 3.1). This 
situation is different from BTV, where only one NS4 type exists (Firth 2008, Ratinier, 
Caporale et al. 2011). Clustal X analysis of the putative ORF for NS4 supported Zwart, 
L., et al. finding that there were two distinct groups of NS4 (Zwart, Potgieter et al. 
2015). Further, our analysis identified three different subtypes in the NS4-II clade 
(Figure 3.1B), which we named NS4-IIα, β and γ. The position of the start and stop 
codons differs among the four groups of NS4 resulting in proteins of different length. 
The NS4 ORFs starts at either nt 214, 148 or 193 of the NS4 ORF and terminates at 
nt 648, 657 or 576, encoding proteins of 144, 169, 154 or 143 amino acid residues 
(Figure 3.1). Unlike the BTV NS4 protein, which is highly conserved, the similarity at 
the amino acid level of the NS4 among different AHSV strains is relatively low and 
ranging between 45.6 and 89.4. 
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Figure 3.1 Schematic representation of AHSV segment 9 ORFs. A. Identification of AHSV NS4-I 
ORF. A 144 aa ORF was detected in the +1 ORF starting at nt 214. B. Identification of NS4-II ORF. 
Three different forms of NS4-II were identified in the +1 ORF including: NS4-IIα, -β and -γ. NS4-
IIβ and γ show either an N- or C-terminal truncation compared to NS4-IIα respectively but they 
share either the same start or stop codon position 
 
Additional AHSV genomic sequences were made available in GenBank in August 2016. 
Analysis of these sequences further supported our initial findings. Interestingly, NS4-
II represented approximately two thirds of more than 200 AHSV segment 9 
sequences; NS4-IIβ represented more than 90% of the NS4-II type.  
The amino acid similarity of NS4 among the NS4-I (Zwart, Potgieter et al. 2015) clade 
is between 94.5 to 100%; whereas, those sequences which belonged to clade II (NS4-
II) show 84.7 to 100% similarity. We observed N- and/or C- terminal truncations in 
different sequences of the NS4-II group. Based on these truncations, NS4-II can be 
further divided (see Figure 3.1B) into three different types (NS4-IIα, β and γ). NS4-
IIα full-length sequence is 169 amino acid residues in length, while NS4-IIβ protein 
has an N-terminal truncation of 15 amino acid residues and NS4-IIγ has a C-terminus 
truncation of 26 amino acid residues (Figure 3.2). There are two very well conserved 
 81 
 
domains in NS4-I and NS4-II between residues 51–70 and 90–143 (in relation to 
sequence JQ742012) (Figure 3.2). In addition, a potential leucine zipper domain is 
present between amino acid residues 92 and 115 of the consensus sequence. We 
found a few NS4 sequences (6 out of the 207 available in GenBank) presenting 
premature stop codons and thus resulting in truncations of the resulting proteins. 
All the viruses with truncated NS4 proteins were either passaged in cell culture or 
in mice. Hence, the biological significance of this truncation is not known. 
 
Figure 3.2. Alignment of representative aa sequences of the four identified NS4 proteins. 
Compared to NS4-IIα, NS4-IIβ had a 15 aa truncation at the N-terminus while NS4-IIγ had a 26 aa 
truncation at the C-terminus. The aa similarity of NS4-I and NS4-II ranged between 45.6% and 
59.5%. Two conserved regions were identified from aa 51 to 70 and from aa 90 to 143. 
 
Phylogenetic analysis of the available AHSV Seg-1, -3, -9 and -10 sequences (carried 
out by Joseph Hughes, using RAxML), revealed that there has been significant 
reassortment within the AHSV genome. Interestingly, the multiple truncations that 
occurred within the NS4-II clade were not linked to the lineages of the other proteins 
(Figure 3.3). It is possible that these NS4-II truncations have occurred due multiple 
separate events although this is not possible to determine based on the current 
analysis. 
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Figure 3.3 Maximum likelihood trees for AHSV NS4 (A) and VP1 (B) based on aa sequence 
alignments. The isolates in both trees cluster into two distinct clades. NS4-I isolates are shown 
in red while NS4-II isolates are shown in blue in both trees. The scale bar corresponds to nt 
changes for the equivalent branch length. Bootstrap value =1,000. 
 
3.2.2 Expression of AHSV NS4 in vitro and in vivo 
Specific antisera against the AHSV NS4 protein were produced commercially 
(Genscript) in order to verify that all four NS4 proteins were expressed in either 
transfected or infected cells. Due to the high level of sequence diversity observed 
between the two NS4 clades, two rabbit polyclonal antisera were generated against 
either full-length NS4-I or NS4-IIβ proteins. To verify that the antisera recognized 
specifically all forms of AHSV NS4, HEK-293T cells were transfected with a 
mammalian expression plasmid (pCI) for either NS4-I, NS4-IIα, β or γ. At 24 h post-
transfection, whole cell lysates were harvested and analyzed by western blotting. 
Specific bands were detected in cell lysates collected from transfected cells but not 
from untransfected controls (Figure 3.4). The apparent size of NS4-I as judged by its 
mobility in SDS-PAGE was slightly higher than the predicted 16.6 kDa (Figure 3.4, 
top panel). On the other hand, NS4-II and migrated to the expected sizes of 
approximately 20 and 17 kDa, respectively. The apparent size of NS4-II was lower 
than expected and closer to 16 kDa rather than the predicted 18.15 kDa (Figure 3.4, 
middle panel). α-tubulin was used as loading control for the western blotting (Figure 
3.4, bottom panel). 
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Figure 3.4. NS4 expression in vitro. HEK-293T cells were transfected with pCI vectors expressing 
NS4-I, NS4-IIα, β or γ (Lanes 1 to 4), pCI-empty (Lane 5) or only treated with Lipofectamine 2000 
(Lane 6). Whole cell lysates were harvested 24 h post-transfection and analyzed by western 
immunoblot using specific antibodies. NS4-I was detected in the upper panel and specific bands 
for NS4-IIα, β and γ were detected in the middle panel. There were no specific bands detected in 
pCI.empty transfected cells with either anti-NS4-I or anti-NS4-II antibodies. α-tubulin was used 
as loading control.  
BSR cells were then infected with the 9 AHSV reference strains (AHSV-1 to -9) in 
order to ensure that NS4 was expressed in the context of viral infection. Whole cell 
lysates were harvested 24 h p.i. and analysed by western immunoblot. NS4-I antisera 
detected the expression of NS4-I in two of the reference strains, AHSV-2 and AHSV-
4, with a band observed at the predicted size of ~16.6 KDa in both (Figure 3.5A). 
The NS4-II antisera, as expected, detected the expression of the NS-IIα, β or γ forms 
by different AHSV strains. AHSV-3 and -6 expressed NS4-IIα; AHSV-2, -7 and -9 
expressed NS4-IIγwhile NS4-IIβ was detected in cells infected with AHSV-1 and -8 
(Figure 3.5B).  
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Figure 3.5. NS4 expression in vivo. A. NS4-I was detected by antisera in AHSV-2 and -4 infected 
BSR cells, whereas NS4-IIα, β or γ were detected in AHSV-3 and -6, AHSV-1, and -8, and AHSV-
2, -7 and -9. AHSV VP7 demonstrated infection and replication of all the viruses in the cell, and 
α-Tubulin was used as loading control of western blot. B. Summary of NS4 mixed expression in 
AHSV reference strains. 
In some cases, we detected multiple bands for NS4 that were not detected in the 
lysates of mock-infected cells. These data may suggest either that NS4 undergoes 
post-translation modifications altering the migration pattern or that different 
transcripts are generated during infection encoding, for example, proteins with 
different initiation codons. However, we cannot rule out the possibility that the 
reference strains that we received could have mixed populations (see Figure 3.5B). 
For example, lysates obtained from cells infected with AHSV-2, seem to display both 
NS4-I and NS4-IIγ proteins. In cells infected with AHSV-5, we detected a band 
corresponding to a truncated NS-4 protein only when immunoblots were overexposed 
(see faint band in Figure 3.5). By sequencing AHSV-5, we confirmed the presence of 
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a premature termination codon that would result in a protein of 66 amino acid 
residues. This is consistent with the analysis described above showing the presence 
of a few sequences with a truncated NS4 in GenBank (section 3.2.1). 
As expected, all 9 different serotypes were positive for VP7 expression while mock-
infected cells were not positive for any form of NS4 or VP7. All lanes had equivalent 
proteins loaded as indicated by the detection of α-tubulin. 
3.2.3 AHSV NS4 localises in the cytoplasm of infected cells 
Bioinformatics analyses using either cNLS Mapper (http://nls-
mapper.iab.keio.ac.jp/cgi-bin/NLS_Mapper_form.cgi) or NoD 
(http://www.compbio.dundee.ac.uk/www-nod/HelpDoc.jsp#PredInfo) were not 
able to identify any NLS (nuclear localization signal) or NoLS (nucleolar localization 
signal) in the NS4 sequences available to us. On the other hand, Zwart and colleagues 
(Zwart, Potgieter et al. 2015) demonstrated by immunofluorescence that both NS4-
I and NS4-II localized to the nucleus of cells infected with BSR cells.  
We addressed these apparent discrepancies by immunofluorescence and confocal 
microscopy. Initially, BSR cells were transfected with plasmids expressing either 
NS4-I, NS4-IIα, β or γ. Twenty-four h post-transfection, cells were fixed and analyzed 
by confocal microscopy using the antisera generated against NS4-I or NS4-II. Both 
AHSV NS4 type I and II were diffused in the cytoplasm (Figure 3.6). No NS4 was found 
in the nucleus or nucleolus. These data was in contrast to the previous study 
published on AHSV NS4 (Zwart, Potgieter et al. 2015). In addition, the NS4 of the 
orbiviruses BTV and GIV also showed nucleolar localization (Belhouchet, Jaafar et 
al. 2011) (Ratinier, Caporale et al. 2011). 
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Figure 3.6. Immunofluorescence showing NS4 expression in the cytoplasm but not in the cell 
nucleus BSR cells were transfected with pCI vectors expressing AHSV NS4-I, NS4-IIα, β or γ 
separately. NS4-I (red) or NS4-II (red) proteins were detected by the corresponding antibody in 
the cytoplasm. The nuclei were stained with DAPI (blue). pCI-empty plasmid was used as mock 
transfection.  
 
The same phenomenon was observed in BSR cells infected with the reference strains 
for either AHSV-4, -6, -1 and -7. These viruses were chosen because they represented 
the viruses expressing the different types of NS4. Cells were fixed 24 h p.i. and 
analyzed by immunofluorescence using confocal microscopy and antibodies for NS4 
or VP7 (the latter used to confirm virus replication)(Figure 3.7). In every case, we 
found NS4 to localize in the cytoplasm and not in the nucleus. We also tried to look 
at the AHSV NS4 localisation in E. Derm cells, however, the results were the same 
(data not shown). 
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Figure 3.7 Immunofluorescence showing NS4 expression in the cytoplasm of AHSV-infected 
cells. BSR cells were infected with AHSV-4, -6, -1 or -7 reference strains. Cells were fixed 24 h 
post infection. Immunofluorescence using specific antibodies for NS4-I and NS4-II detected all 
forms of NS4 (red) in the cytoplasm. The nuclei were stained with DAPI. To ensure that there 
was virus replication an antibody to detect VP7 (red) was used as a control (middle panel). Since 
both NS4 and VP7 antisera were raised in rabbit, we were unable to detect NS4 and 
VP7expression in same cell. 
 
3.2.4 The effect of the AHSV NS4 on gene expression 
In a previous study, it was shown that BTV NS4 has an effect on cellular protein 
expression (Ratinier, Shaw et al. 2016). Here, we also assessed the effect of AHSV 
NS4 on gene expression using a luciferase reporter system. CPT-Tert cells were co-
transfected with a CMV-driven expression plasmid, which expresses firefly 
luciferase, and expression plasmids for either AHSV NS4-I, NS4-IIα, β or γ. The effect 
on luciferase production caused by AHSV NS4 was evaluated by measuring luciferase 
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signal (Figure 3.8A). The empty pCI plasmid was used to normalise the data (Figure 
3.8B). BTV-NS4 was used as positive control while BTV-NS2 as negative control. NS4-
IIβ had the greatest effect of luciferase expression and caused ~75% decrease in 
luciferase expression in comparison to the pCI empty plasmid, similar to what is 
observed with BTV NS4. In contrast, NS4-IIγ had nearly no effect on luciferase 
expression, like the negative control BTV NS2. AHSV Type I and IIα NS4 had similar 
effects on luciferase expression causing an approximately a 25% reduction of the 
luciferase signal. 
 
Figure 3.8. Role of AHSV NS4 on cellular protein shutdown. 100 ng of each NS4 expression 
plasmid or pCI.empty plasmid together with 100 ng of CMV-driven firefly luciferase plasmid and 
300 ng of pCI.empty plasmid were co-transfected into CPT-Tert cells. Luciferase activity was 
measured 22 h post-transfection. BTV8-NS4 acted a positive control and BTV10-NS2 was used 
as a negative control. A. Dot plot showing the RLU from three independent experiments 
highlighting the reproducibility of the assay and the differences among the different NS4 
proteins. NS4-IIβ reduced luciferase expression whereas NS4-IIγ had little effect on luciferase 
expression. B. Bar plot showing luciferase activity relative to the pCI.empty control that was set 
at 100%. NS4-I, NS4-IIα, β or γ decreased luciferase expression by ~28%, 24%, 75% and 6% 
respectively. C. Dose dependent effect of NS4-II and NS4-IIon luciferase activity. Decreasing 
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concentrations of NS4 expression vector were transfected with 100 ng of CMV-driven luciferase 
into CPT-Tert cells. D. Effect of N- and C- terminal NS4 deletions on luciferase activity. N-
terminus NS4-IIβ deletion increased luciferase activity by 43% to 79%, whereas C-terminus NS4-
IIγ deletion decreased luciferase activity from ~99% to 83%. Each experiment was performed 
three times, each time in duplicate.  
 
In order to determine whether the effects on gene expression were dose dependent, 
different amounts of NS4-IIβ or IIγ expression plasmids were co-transfected with the 
luciferase reporter vector and the luciferase signals measured at 22 h post 
transfection. NS4-IIβ inhibited luciferase expression in a clear dose-dependent 
manner (Figure 3.8C). In contrast, there was no dose effect displayed by NS4-IIγ.  
Considering the differences between the β and γ subtypes of AHSV NS4-II, we 
generated expression plasmids for NS4II-β lacking the C-terminus domain (NS4II-β-
∆C-ter) and NS4-IIγ lacking the N-terminal region of the protein (NS4-IIγ-Nter). When 
the C-terminus of NS4-IIβ was removed, its ability to reduce the luciferase 
expression was dramatically lost (Figure 3.8D) from ~40% to 21%; however when the 
C-terminus of NS4-IIγ was deleted, it had little effect on its ability to reduce 
luciferase activity.  
 
3.2.5 AHSV NS4-IIβ and -IIγ expression induces apoptosis 
We observed that BSR cells either transfected with AHSV NS4-IIβ expression plasmid 
or infected with AHSV-1 (which contains NS4-IIβ) by immunofluorescence showed 
morphological hallmarks of cell apoptosis (Figure 3.9). Cells expressing NS4 shrank, 
the cytoplasm appeared denser and nuclei had an abnormal morphology with obvious 
blebbing of the cell membrane. On the other hand, cells transfected with an 
expression plasmid for NS4-IIγ or infected with a virus expressing this protein did not 
show these characteristics. 
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Figure 3.9 Immunofluorescence showing morphological changes to BSR cells transiently 
transfected with expression vectors for NS4-IIβ or NS4-IIγ or infected with AHSV-1 reference 
strain. NS4-II (red) was detected using a specific antibody while the nuclei were stained with 
DAPI (blue). Cells expressing NS4-IIβ alone or in the context of virus infection (AHSV-1 reference 
strain) displayed hallmark signs of apoptosis. The abnormal shaped nucleus and membrane 
blobbing were not observed in mock transfected or infected cells. 
In order to confirm these visual observations, and to verify that indeed 
transfected/infected cells were apoptotic, we measured the levels of activated 
caspase3/7 as a marker of apoptosis (Slee, Adrain et al. 2001) in NS4-IIβ or γ 
transfected cultures using a luciferase assay. Stautosporine was used as positive 
control, while pCI-empty was used as negative control (Bertrand, Solary et al. 1994). 
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A caspase-3/7 luciferase kit was used to measure the quantity of caspase-3/7 at 3, 
6, 9, 12 and 22 h post-transfection. We detected activated caspase 3/7 in both NS4-
IIβ and IIγ transfected cells from 6 h post-transfection (Figure 3.10). Even though 
there were morphological differences observed by confocal microscopy (Figure 3.9), 
there were no significant differences in the induction of caspase3/7 between NS4-
IIβ and γ transfected cells (Figure 3.10B).  
 
Figure 3.10 NS4-IIβ activation of caspase-3/7. BSR cells were transfected with pCI.NS4-IIβ, 
pCI.NS4-IIγ, pCI.empty plasmid or treated with staurosporine. Cell lysates were collected 3, 6, 9, 
12 and 22 h post transfection. Caspase 3/7 activity was measured by the release of firefly 
luciferase after specific cleavage of the substrate. NS4-IIβ and NS4-II γ expression induced the 
activation of caspase 3/7 overtime. A. RLU of firefly activity at different time points post 
transfection or after the addition of staurosporin. B. Influence of NS4-IIβ and γ on luciferase 
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activity. Values relative to the pCI.empty control are plotted. Each experiment was performed 
three times, each time in duplicate. 
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3.1 Discussion 
This chapter reports that segment 9 from essentially all AHSV strains sequenced to 
date (with a handful of exceptions) express a NS4 protein. NS4 is encoded by a +1 
alternative ORF overlapping the VP6 ORF and as expected follows the VP6 phylogeny. 
Previous studies revealed that the segment 9 of BTV and other orbiviruses such as 
ENDV-1, AHSV-3, PHSV, YUOV-1 and GIV is olycistronic (Firth 2008, Belhouchet, 
Jaafar et al. 2011, Ratinier, Caporale et al. 2011). Although some of the genome 
segments of the family Reoviridae were also found to be multicistronic (for example 
Phytoreovirus) (Suzuki, Sugawara et al. 1996), this +1 alternative overlapping ORF 
in segment 9 was only present in the genus orbivirus (Firth 2008). Although, no one 
has formally demonstrated that AHSV NS4 is a non-structural protein, due to the 
parallel drawn with BTV NS4, we and others have made that assumption by adopting 
the name NS4 (Ratinier, Caporale et al. 2011, Zwart, Potgieter et al. 2015). 
Analyzing all the AHSV sequences available in GenBank, two types of NS4 were 
identified and named NS4-I and NS4-II. About a quarter of the AHSV strains express 
a NS4-I protein while the remaining possess a NS4-Iiβ protein. Further analysis 
indicated that NS4-II could be split into three subtypes, α, β and γ based on amino 
acid sequences and the presence of either N- or C-terminal truncations. Interestingly 
more than 90% of the NS4-II sequences were of β subtype. Phylogenetic analysis of 
NS4 suggested that it evolved independently from other segments and as expected 
was independent from virus serotype.  
Reassortment is a common occurrence in the viruses whose genomes are composed 
of multiple segments, including reoviruses and orthomyxoviruses (Nomikou, Hughes 
et al. 2015) (Wenske, Chanock et al. 1985, Jones, Davies et al. 1987). AHSV is also 
shown to reassort in the field (Weyer, Quan et al. 2013). Zebras are considered the 
natural reservoir of AHSV, and it has been shown that the same animal can harbor 
different strains/serotypes simultaneously (Barnard 1993), therefore facilitating 
reassortment and the generation of viruses different from either parental strains. It 
is interesting to note that we detected multiple specific bands for NS4 in western 
blotting analysis of cells infected by the different South African strains of AHSV. The 
data may suggest either that NS4 undergoes post-translation modifications or use 
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different initiation codons. We cannot rule at this stage that the reference strains 
that we received could have a mixed populations containing different segment 9. In 
AHSV reference strain serotype 5, NS4 was truncated and composed of only 66 amino 
acids. Similar truncations were also observed in 6 of the 207 AHSV segment 9 
sequences found in GenBank. However, these AHSV isolates have been passaged in 
cell culture (including Vero cells, BHK cells and BSR cells) and/or in mice over 5 
times and may therefore simply represent cell-adapted strains. 
Amino acid sequence analysis suggested that AHSV NS4 contains a putative leucine 
zipper-like domain at the C-terminus of the protein. This domain is also found in BTV 
NS4 (Ratinier, Caporale et al. 2011) and it is similar to domains found in the 
transcription factors of the bZip family (Vinson, Myakishev et al. 2002). Interestingly, 
a previous study suggested that AHSV NS4 binds dsDNA but not dsRNA (Zwart, 
Potgieter et al. 2015), whereas BTV NS4 has been found to bind both dsRNA and 
dsDNA (Belhouchet, Jaafar et al. 2011). Although it is hypothesized that the leucine 
zipper was involved in DNA binding, here we observed that the AHSV NS4 localizes 
in cytoplasm and not in the nuclei of infected cells. Thus, it is not immediately clear 
whether the DNA binding motif could actually function in the host genomic DNA.  
BTV NS4 was shown to affect host protein synthesis. Here we observed using 
luciferase assays that the AHSV NS4 protein inhibits gene expression. The C-terminal 
domain of this protein is presumed to be important for this function. In comparison 
to other forms of AHSV NS4, AHSV NS4-IIγ has only a weak effect on gene expression 
and lacks the C-terminal 26 amino acid residues where the putative leucine zipper 
is located. NS4-IIβ lacks the N-terminal 15 amino acid residues but appeared to have 
the strongest inhibitory activity on cellular gene expression. It is not clear at this 
stage how AHSV NS4 blocks gene expression and if this effect can also be seen in the 
context of virus infection. The BTV NS4 protein appears to modulate expression of a 
variety of promoters including IFNβ and Interferon-stimulated response elements 
(ISREs). For these reasons, the BTV NS4 is considered an interferon antagonist 
(Ratinier, Shaw et al. 2016)  
However, in our experiments the AHSV NS4 protein localizes to the cytoplasm, rather 
than the nucleus/nucleolus as BTV NS4 (Ratinier, Caporale et al. 2011, Zwart, 
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Potgieter et al. 2015). Indeed, we found no nuclear or nucleolar localization signals 
in any of the AHSV NS4 sequences. These data are in disagreement with a previous 
study where the authors found AHSV NS4 to localize in the nucleolus. We noticed 
that Zwart et al. generated antisera against NS4-I or NS4-II using the peptides 
QGAGLEGEEWAEWL or MIEEWRARNLREAD (Zwart, Potgieter et al. 2015). With these 
particular peptides we found homology (Using ProteinBlast in NCBI) to other cellular 
proteins including the nuclear transport factor 2 family protein and 
serine/threonine-protein phosphatase. Therefore, the antisera generated in that 
study could be detecting host rather than viral proteins. 
In summary, in this chapter, we have identified four different forms of NS4 that are 
present in the AHSV genomes available in GenBank. Importantly, we found the AHSV 
NS4 protein to be expressed in infected cells. All the four forms of the AHSV NS4 
proteins localized to the cytoplasm of infected cells. In the following chapters we 
will further characterize the function of this protein.  
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 Establishment of a reverse genetics system for AHSV 
4.1 Introduction. 
The data generated in chapter 3 supported the previously published data from Firth, 
et al. and Zwart, et al. that an alternative ORF in segment 9 of AHSV encodes a 
small non-structural protein (termed NS4) (Firth 2008, Zwart, Potgieter et al. 2015). 
Furthermore, we showed that there are phylogenetically distinct clades of NS4 (I 
and II) and one of these clades can be further subdivided into three distinct groups 
on the bases of their initiation and stop codons. We showed that NS4 is expressed 
by all AHSV strains. Therefore, in order to systematically determine and study the 
function(s) of NS4 in the context of the viral life cycle, we set up to use a reverse 
genetic system in order to introduce modifications into the viral genome and obtain 
NS4 deletion mutants.  
Reverse genetics systems (RG) have been used widely to study the role of viral 
proteins during virus replication. The first report of cDNA being used to recover 
infectious viral progeny was by Racaniello et al. for the rescue of poliovirus 
(Racaniello and Baltimore 1981). RG allowed the introductions of mutations into 
specific domains of viral proteins or into RNA structures important for the control of 
virus replication. Since this discovery, numerous reverse genetic systems have been 
developed to study a variety of RNA and DNA viruses. For example, the use of 
infectious molecular clones for HIV allowed to understand the biological function of 
many of its accessory proteins (Freed 2001). 
The development of a RG system for dsRNA segmented viruses occurred relatively 
recently. A major breakthrough occurred after it was shown that reovirus serotype 
3 (ST3) ssRNA generated in vitro using purified core particles was infectious after 
transfection into mammalian cells (Roner, Sutphin et al. 1990). BTV, the 
representative virus of genus Orbivirus, was first rescued in 2008 (Boyce, Celma et 
al. 2008) and since this date, there have been numerous systems developed including 
the use of helper viruses, plasmid only, two-step protocols with either ssRNA, DNA 
+ssRNA or DNA (Roner and Joklik 2001, Kobayashi, Antar et al. 2007, Matsuo and Roy 
2009, Kaname, Celma et al. 2013, Conradie, Stassen et al. 2016). To date, the BTV 
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RG system has been used to answer key questions on the roles of structural proteins 
(VP2, VP4) and two of the non-structural proteins (NS3 and NS4). Advances in the 
BTV RG system allowed the application of this technology also to AHSV. In 2013, 
Kaname et al. (Kaname, Celma et al. 2013) published the recovery of AHSV using a 
similar method that had been used for BTV. Since then, Van de Water et al. (Van de 
Water, van Gennip et al. 2015) have published further refinements on the methods 
used to rescue AHSV while more recently, a plasmid-only method was successfully 
developed (Conradie, Stassen et al. 2016).  
The development of a successful AHSV RG system will provide a platform on which 
to build a better understanding of the role of NS4 on virus biology. It could be used 
to address key questions on its function and determine if there is functional 
homology with the related orbivirus NS4 proteins. 
This chapter aims to develop a RG system based on the AHSV-4 serotype. This 
technology will allow the rescue of virus reassortants containing genome segment 9 
from other AHSV strains in order to develop all the reagents necessary to study the 
different types of NS4 proteins and corresponding deletion mutants.  
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4.2 Results 
4.2.1 Establishment of a reverse genetic system for AHSV. 
In order to establish a RG system for AHSV, the sequence of the AHSV-4 reference 
strain was download from GenBank (accession No. JQ796724 to JQ796733), cDNA 
copies of each genome segment were synthesized commercially (Genscript) and 
inserted into plasmids that were designed similarly to what already described 
(Boyce, Celma et al. 2008, Kaname, Celma et al. 2013). Briefly, the cDNA copy of 
the genome segment, including the untranslated region (UTR) and coding region, 
was placed downstream a T7 promoter (TAATACGACTCACTATAG) and unique 
restriction endonuclease cutting sites at the 5’ and 3’ end extremities. This design 
enables the generation of transcripts mimicking the core transcripts to be generated 
by in vitro synthesis. cDNA sequences for each segment (with the exception of 
segment 3) were cloned into pUC57 (Figure 4.1A), a high copy plasmid as it contains 
a pMB1 origin of replication. Segment 3 was instead cloned into pJet1.2, a low copy 
plasmid. 
 
Figure 4.1 Schematic representation of the constructs used to generate viral mRNA (A) and to 
express viral proteins (B). A. An exact copy of the full-length AHSV-4 segment 9 was cloned into 
the pUC57 vector flanked by a T7 promoter at the 5’ end and a restriction endonuclease site 
(BsaI) at 3’ end in order to create a correct 3’ end of the transcript. B. The full-length AHSV-4 
segment 9 was cloned into pCI that contains a CMV promoter and CMV enhancer at 5’ end. 
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4.2.2 In vitro transcription  
The quality of ssRNA generated from the plasmid during in vitro transcription is 
critical for the rescue of an infectious virus. The ssRNA needs to be an exact copy of 
the AHSV viral genome, as these RNA segments are then used as the templates to 
synthesize the genomic dsRNA. In order to prepare the genome ssRNA for reverse 
genetic, plasmids containing the genomic segments of AHSV-4 were cut and 
linearized with the designed restriction endonuclease and then purified by phenol-
chloroform. Viral genome ssRNAs were in vitro transcribed, using purified plasmids 
as templates, by mMESSAGE mMACHINE T7 Ultra Kit (Ambion), purified initially by 
phenol-chloroform extraction and then through an Illustra Microspin G25 column.  
The length and quality of the synthesized ssRNA was analyzed by a Bioanalyzer 
Instrument 2100 (Agilent) following the manufacturer’s instructions (Figure 4.2). The 
output from the Bioanalyzer demonstrated that the ssRNA generated was of a high 
quality and of the expected size. In each picture, the smaller peak of 25 nt indicated 
the dye of the ssRNA in the loading buffer, and the following larger peak showed the 
length of each ssRNA segment. The last lane showed the ladder (Figure 4.2A). The 
width of each peak suggested the integrity of the ssRNA. Briefly, the sharper the 
peak, the more integrity of each ssRNA segment. The width of segment 1 peak 
suggested that some of the ssRNA molecules were degraded, however, most of the 
ssRNA segments were intact. In order to provide a better view of each RNA segment, 
the Bioanalyzer also performs simulated gel electrophoresis run in the presence of 
a ladder (Figure 4.2B). This mimics the ssRNA migration in 1% TAE agarose gel 
electrophoresis. Samples were also run in a 1.5% TAE agarose gel electrophoresis, 
and the result was the same as the simulated migration results (data not shown).  
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Figure 4.2 Analysis of the integrity of T7-generated ssRNA of the 10 segments of AHSV-4 using 
an Agilent 2100 Bioanalyzer Instrument. Samples 1 to 10 represent ssRNA of AHSV-4 genome 
segments 1 to 10. Sample 11 represents BTV-1 segment 3 that was used as the positive control. 
A. Electropherogram of each segment. The peaks indicate the length and purity of the samples. 
The peak at 25 is the loading dye. B. Simulated gel electrophoresis image of the migration 
pattern of the ssRNA.  
 
4.2.3 Rescue of AHSV-4 by reverse genetics. 
The ssRNA was of sufficient quality to be used to test a two-step AHSV RG system 
(Matsuo, Celma et al. 2010). However, the initial experiments using this protocol 
either failed or the rescue efficiency was very low. Thus, the method described by 
Kaname et al. and Van de Water et al. (Kaname, Celma et al. 2013, Van de Water, 
van Gennip et al. 2015) was subsequently followed. BSR cells were initially 
transfected with expression plasmids encoding AHSV-4 VP1, VP3, VP4, VP6, NS1 and 
NS2 (100 ng each). For this scope cDNAs of AHSV4 segment 1, 3, 4, 5, 8 and 9 were 
cloned into the pCI plasmid, which contains the CMV promoter (Figure 4.1B). The 
transfection of these plasmids enabled the expression of the transcription complex 
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and the formation of inclusion bodies prior to transfection of 1011 molecules of ssRNA 
corresponding to each of the AHSV-4 10 genomic segments (see Figure 4.3 for a 
diagram of the method). To ensure that the protocol was optimized for the recovery 
of orbiviruses, BTV-1 was used as positive control throughout the RG process 
(Ratinier, Caporale et al. 2011). Negative controls, included cells transfected with 
ssRNA corresponding to 9 of the 10 AHSV-4 genomic segments and mock-transfected 
cells. Cytopathic effect in BSR cells was visible after 72 hours in cells transfected 
with AHSV-4 10 ssRNAs, but not in the negative controls. dsRNA was then extracted 
from the BSR cells were AHSV-4 was rescued (termed from now on “rgAHSV-4” for 
RG AHSV-4) and from BSR cells infected with AHSV-4 used as control. Results showed 
all 10 segments of rgAHSV-4 were present and the migration pattern was the same 
as the AHSV-4 reference strain (Figure 4.4). 
 
Figure 4.3 Schematic representation of the 2-step reverse genetic protocol for the recovery of 
AHSV. Plasmids expressing VP1, VP3, VP4, VP6, NS1 and NS2 were transfected into BSR cells. 
Eighteen 18 h post-transfection, 1011 molecules of each of the 10 AHSV T7-generated ssRNA 
were further transfected. Cells were monitored for CPE or morphological changes for a minimum 
of 48–72 h. 
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Figure 4.4 Migration pattern of genomic dsRNA extracted from rescued AHSV-4 in comparison 
to dsRNA extracted from the AHSV-4 reference strain. The migration of the segments was the 
same between the rescued and reference strain AHSV-4 viruses. Rescued BTV-1 dsRNA was 
used as a control.  
 
4.2.4 Recovery of AHSV segment 9 reassortants and NS4 deletion mutants. 
Next, we generated AHSV-4 reassortants with segment 9 from either AHSV-7 
(JQ742012), AHSV-1 (AM883170) or AHSV-6 segment 9 (AHU33000) in order to have 
viruses within the same genetic background expressing NS4-IIα, β and γ respectively. 
rgAHSV-4 instead represented a virus expressing NS4-I. The reassortants are named 
from now on rgAHSV4-NS4-I, -NS4-IIα, -NS4-IIβ and -NS4-IIγ. In addition, we 
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generated for both the “wild type” rgAHSV-4 and the segment 9 reassortants 
described above, NS4 deletion mutants. To generate AHSV NS4 deletion mutants, 
extra care was taken to ensure that coding region of the overlapping VP6 reading 
frame was not disrupted. The start codon of the NS4 ORF and following downstream 
ATG codons were mutated and several stop codons were introduced inside the NS4 
ORF without changing any aa residue of the AHSV VP6 protein (Figure 4.5). The 
sequences of all the viruses rescued by reverse genetics were verified by Sanger 
sequencing. Note that the aa similarity among the VP6 proteins encoded by the AHSV 
strains encoding NS4-II proteins is between 93.8% to 96.5%. While the VP6 of AHSV-
4 (expressing NS-I) is approximately 63% similar to the type II proteins. 
 
Figure 4.5. Examples of mutations introduced into AHSV-4 segment 9 to stop expression by 
mutation of the start codon (A) or by the introduction of an early stop codon (B). The wt aa 
sequences of VP6 and NS4-I are presented above the wt nt sequence. The nt to be mutated is 
boxed in red and the changed nt sequence is given below along with the VP6 and altered NS4 
sequence.  
 
4.2.5 NS4 is not essential for AHSV-4 replication 
The validation of an AHSV RG system using wt virus and the generation of constructs 
that would enable recovered viruses to express the different forms of NS4 and their 
respective deletion mutants allow us to test whether NS4 was essential for virus 
replication. Previous studies showed that the BTV NS4 was not required for the 
efficient rescue of BTVs (Ratinier, Caporale et al. 2011). Indeed, wt AHSV-4 
expressing NS4-I, NS4-IIα, -IIβ or -IIγ, and the corresponding ΔNS4 viruses were all 
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successfully rescued. These data indicated that similarly to BTV, AHSV NS4 is not 
essential for replication, at least in BSR cells. 
Next we assessed the replication kinetics of all the rescued viruses and their ability 
to induce plaques in BSR cells. We also analyzed the genomic dsRNA profile and 
protein expression. All rescued viruses were passaged once in BSR cells and then 
plaque assays were carried out also in BSR cells. Plaque size and morphology was 
examined 72 h p.i. by staining the monolayer with crystal violet. All recovered 
viruses formed plaques in BSR cells (Figure 4.6) and there was no obvious difference 
in the plaques regardless of whether it was the wt or corresponding ΔNS4 recovered 
virus. 
 
Figure 4.6. Plaque morphology of AHSV expressing NS4-I, NS4-IIα, NS4-IIβ or NS4-IIγ and the 
respective NS4 deletion viruses. BSR cells were infected and overlaid with 1.5 % low melting 
point agarose for 72 h when monolayers were fixed and stained with crystal violet. The top panel 
shows the plaques formed by AHSV-4 NS4-I, -IIα, -IIβ or –IIγ, whereas in the bottom panel are 
the plaques from the corresponding ΔNS4 viruses. The shape and size of the plaques are 
comparable between wt and ΔNS4 viruses.  
In addition, analysis of dsRNA from all the reassortants and NS4 deletion mutants did 
not reveal any difference with wt AHSV. (Figure 4.7). In addition, to ensure that the 
segment 9 mutations had been maintained after rescue, we amplified the VP6 ORF 
(which includes also the NS4 ORF) by RT-PCR from all reassortants and sequenced 
the resulting products. Analysis of the sequence chromatograms showed that all the 
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mutations had been maintained after virus recovery. Importantly, no additional 
mutations were introduced into the coding sequence of VP6 and NS4 ORF. 
 
Figure 4.7 Migration pattern of dsRNA of rescued AHSV viruses. The migration pattern of the 
genomic segments was the same between the rescued wt and the NS4 AHSV-4 viruses. 
 
Next, BSR cells were infected and after 24 h cell lysates were harvested and analyzed 
by western blotting in order to ensure either NS4 expression (or lack of) from wt and 
corresponding NS4 deletion mutants. For all of the ΔNS4 viruses, no NS4 expression 
was detected (Figure 4.8). This indicated that the mutations introduced into 
segment 9 stopped NS4 expression as expected. On the other hand, AHSV-4 wt and 
the segment 9 reassortant viruses expressed the various types of NS4 (Figure 4.8, 
top panel). Of note, the relative expression of NS4-II appeared to be higher than 
that of the other either types of NS4. The NS4-I polyclonal antisera detected both 
NS4-I and NS4-IIα, likely because of conserved epitopes between NS4-I and NS4-II 
(discussed in chapter 3) and the relatively high levels of expression. The 
monospecific polyclonal NS4-II antisera, as expected, did not detect NS4-I expression 
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by western blot. VP7 expression was also assessed in order to control that cells had 
been infected with replicating viruses (Figure 4.8; third panel) while α-tubulin was 
used as a loading control. 
 
Figure 4.8 Western immunoblot to examine expression of NS4 in wt and mutant viruses. BSR 
cells were infected at MOI ~0.01 and cell lysates harvested 24 h post infection. The samples were 
probed with antibodies against NS4-I, NS4-II, VP7 or α-tubulin. Single expression of either AHSV-
4 NS4-I, -IIα, -IIβ or -IIγ was detected in the wt viruses but not in the corresponding mutant 
viruses. Interestingly, NS4-IIα was detected by the anti-NS4-I antibody. Anti-VP7 and α-tubulin 
were used as controls of viral replication and loading respectively.  
 
4.2.6 Replication kinetics of NS4 reassortants and ΔNS4 viruses in BSR cells. 
Thus far, we showed that segment 9 from different strains of AHSV-4 easily 
reassorted into the AHSV-4 backbone. Furthermore, the successful rescue of the 
ΔNS4 mutants clearly indicated that NS4 is dispensable for AHSV replication in BSR 
cells (Kawai, Matsumoto et al. 1975).  
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Next, we assessed the replication kinetics of segment 9 reassortants and NS4 
deletion mutants. BSR cells were infected at an MOI of 0.01, cell-free viruses were 
harvested at 24, 48 and 72 h p.i. and titrated by standard endpoint dilution assays. 
In all cases, the presence of NS4 did not affect the replication kinetics of AHSV 
(Figure 4.9). We noticed however the viruses with segment 9 from AHSV-4 and AHSV-
7 reached higher titres than reassortants with segment 9 from AHSV-1 and AHSV-6. 
These patterns were similar however, in the absence of NS4 this can be attributed 
likely to differences in the VP6 between different proteins. 
 
Figure 4.9 Virus growth kinetics in BSR cells. BSR cells were infected with AHSV-4 NS4-I, NS4-
IIα, β, or γ and the corresponding ΔNS4 viruses at MOI 0.01. Cell-free virus was harvested at the 
indicated time points and the titre was determined by limiting dilution and expressed as 
TCID50/ml. The growth kinetics of ΔNS4 viruses (blue) were similar to the related wt viruses (red). 
Each experiment was performed independently three times using two independently generated 
virus stocks. 
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4.3 Discussion 
When developing the RG system for AHSV, there were a number of different 
approaches that could have been undertaken. A helper virus could have been used 
to recover infectious particles in a similar manner as the first RG system developed 
for the Reoviridae (Roner, Sutphin et al. 1990, Roner and Joklik 2001) or a plasmid-
based system (Kobayashi, Antar et al. 2007). We discarded this option as this method 
may provide elements of confusion in distinguishing the helper virus from the 
rescued one. Instead, I based our approach on the existing systems that had been 
published for both BTV and AHSV. This initially involved a two-step transfection of 
ssRNA (Matsuo and Roy 2009). Briefly, in the first step, ssRNAs of the segments that 
encode the transcription complex (VP1, VP3, VP4, VP6) and two non-structural 
proteins (NS1 and NS2) are transfected into BSR cells. After 18 h, cells are 
transfected again with all the 10 ssRNAs. This method was shown to work for both 
BTV and AHSV (Ratinier, Caporale et al. 2011) (Matsuo, Celma et al. 2010) but in our 
hands the rescue efficiency was very low.  
We then used a modification of this protocol with the first step using expression 
plasmids for the polymerase complex, NS1 and NS2, instead of ssRNA. The CMV 
promoter in the pCI expression plasmid likely allow high levels of protein expression, 
which may be required to create an optimal “cellular environment” for the rescue 
of the 10 ssRNAs. The expression plasmids used in this study were an exact cDNA 
copy of the viral genomic segment and included the UTR rather than just the coding 
regions. The UTR of these segments were maintained in the constructs based on the 
published study showing that BTV NS1 preferentially up-regulates viral protein 
expression over host cell proteins by binding the UTR of the viral genome segments 
(Boyce, Celma et al. 2012). Also, unlike the method used by Van de Water et al. the 
expression of VP7 was excluded from the first round transfection. The data 
presented in this chapter supports the notion that the transcription complex is 
critical for AHSV rescue and that a two-step protocol using DNA, followed by ssRNA, 
increased the efficiency of the method.  
Since developing this method, a further RG system was developed for AHSV solely 
based on plasmids and using a T7-expressing cell line. Although this approach would 
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be a cheaper and quicker alternative to the synthesis and purification of ssRNA, in 
our hands we were not able to clone some of the segments in some expression 
plasmids as already described in other systems (Casais, Thiel et al. 2001, Thiel, 
Herold et al. 2001, Ward and Davidson 2008, Zhou, Jerzak et al. 2011). 
Like BTV, AHSV can readily reassort (Meiring, Huismans et al. 2009, Weyer, Grewar 
et al. 2016). In this chapter, it was demonstrated that AHSV-4 could reassort with 
segment 9 from two different clades. Indeed, the two different clades of VP6 (see 
chapter 3) share 63% similarity at the aa level (AHSV VP6 clade I Vs II), indicating 
that there must be conservation of structural domains that confer functional 
homology between this essential protein. Deletion of VP6 has been shown to prevent 
rescue of the virus (Matsuo, Celma et al. 2010). AHSV VP6, like BTV VP6, has been 
reported to be an RNA binding protein and acting as a helicase to unwind viral 
genomic RNA (De Waal and Huismans 2005).  
To date, the role of AHSV NS4 in virus replication has not been studied. Initial studies 
by Zwart. et al. (Zwart, Potgieter et al. 2015) had used recombinant protein 
technology to investigate the role and functions of AHSV NS4. These authors 
demonstrated that NS4 has a dsDNA binding activity but due to the lack of a reverse 
genetic system, they were unable to determine its importance during virus 
replication.  
In this chapter, we successfully rescued AHSV-4 reassortants expressing the 4 
different forms of the NS4 protein and the corresponding NS4 deletion mutants.  
We established that NS4 was not essential for replication in BSR cells. Furthermore, 
the viral replication kinetics of wt and ΔNS4 viruses was similar between the 
respective viruses. However, there appeared to be differences in the replication 
kinetics among the wt viruses expressing different VP6. The ability of the AHSVNS4 
viruses to replicate in BSR cells was similar to what had been already reported for 
BTVΔNS4 mutants (Ratinier, Caporale et al. 2011). These data so far suggest that 
there may be some functional homology between the NS4 proteins of these two 
different orbiviruses. In the next Chapter we will focus on trying to understand the 
role of the NS4 in AHSV biology. 
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 The AHSV NS4 modulates the host IFN response 
5.1 Introduction 
In Chapter 4, a reverse genetics system for AHSV-4 was established and viruses that 
expressed the four types of NS4 identified in this thesis were rescued. Furthermore, 
viruses that did not express NS4 were also rescued. AHSV-4, segment 9 AHSV 
reassortants and NS4 deletion mutants induced similar plaque morphology and 
possessed similar replication kinetics in BSR cells. These data clearly indicated that 
the NS4 is not essential for virus replication similarly to what previously observed 
with BTV (Ratinier, Caporale et al. 2011). However, the BTV NS4 provides a 
replicative advantage to the virus in IFN competent cells and is a determinant of 
virus virulence in vivo in sheep (Ratinier, Shaw et al. 2016). As BSR cells are IFN 
incompetent, which do not produce IFN and response to IFN from extracellular 
matrix, it is possible that the AHSV NS4, similarly to the BTV NS4, modulate the IFN 
response of the host.  
The type I IFN response is one of the immediate barriers to viral infection deployed 
by the host innate immune system. Viruses have evolved a variety of mechanisms to 
counteract the antiviral immune responses of the host. Viral proteins expressed by 
several viruses directly hamper IFN induction or response and antagonize the host 
immune system. Often these viral proteins are non-structural and are not essential 
for virus replication but they are absolutely necessary to subvert the innate immune 
response that hinder replication. Well-studied examples of these IFN antagonists 
include for example the influenza virus NS1 (Talon, Horvath et al. 2000), the 
orthobunyaviruses NSs that counteracts IFN induction (Weber, Bridgen et al. 2002) 
and the HIV-1 Vpu or VIF proteins (Van Damme, Goff et al. 2008).  
The induction of interferon in response to AHSV infection and virus modulation of 
this response has not been studied in detail to date. The only data examining the 
type I IFN response for AHSV comes from studies in mice (de la Grandière, Dal Pozzo 
et al. 2014) indirectly demonstrating that IFN has a role in controlling infection. 
Indeed, wild type mice are resistant to AHSV infection but knock-out mice for the 
type-I IFN receptor (IFNAR-/-) are instead killed by the same virus. The interaction 
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of BTV with the host IFN response has been instead better characterised. At least 
two of the viral non-structural proteins of BTV have been shown to modulate the IFN 
response. NS3/NS3A was highlighted as a potential IFN antagonist by its ability to 
shutdown host cell protein synthesis and reducing the levels of IFN-β mRNA 
transcripts (Chauveau, Doceul et al. 2013, Vitour, Doceul et al. 2014). As mentioned 
before, also the BTV NS4 modulated the IFN response (Ratinier, Caporale et al. 2011, 
Ratinier, Shaw et al. 2016) with a mechanism that has not been clarified completely. 
NS4 appears however to act at transcriptional level inhibiting gene expression of a 
variety of promoters. Our hypothesis is that AHSV shares functional homology in its 
ability to antagonise the IFN response to a similar extent to BTV NS4, even though 
they localise to different regions of the cells. In this chapter therefore, we aim to 
examine the role of the AHSV NS4 in virus replication in vitro and pathogenesis in an 
experimental model of the disease.  
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5.2 Results 
5.2.1 NS4 is not required for AHSV replication in culicoides cells 
AHSV is an arbovirus transmitted by culicoides midges. Hence, the virus is adapted 
to grow both in mammalian and insect cells. Hence, we addressed whether the AHSV 
NS4 had a role in virus replication in insect cells, using a cell line (Kc) derived from 
Culicoides sonorensis (Wechsler, McHolland et al. 1991). 
Kc cells were infected with either AHSV-4, the AHSV segment 9 reassortants or the 
corresponding deletion mutants at an MOI equivalent of 0.01 (in BSR cells). 
Supernatants were collected at 24, 48 and 72 h p.i. and titrated by endpoint dilution 
assays in in BSR cells. No differences were observed between the replication kinetics 
of the viruses possessing the NS4 as opposed to the corresponding NS4 deletion 
mutants (Figure 5.1A).These data indicate that NS4 does not play a significant role 
in AHSV replication in culicoides cells. 
5.2.2 NS4-I, -IIα and -IIγ provide a replicative advantage to AHS in E. Derm cells. 
We next investigated the role of NS4 in AHSV replication in horse cells. E. Derm is 
an IFN competent cell line derived from the dermis of a 4 year old female horse 
(ATCC). E. derm were infected with either AHSV-4, or the various reassortants 
described above and the NS4 deletion mutants, and supernatants collected and 
titrated as described above for Kc cells. We observed that the titre of the virus 
expressing NS4-I was ten folds higher than the corresponding ΔNS4-I mutant (Figure 
5.1B) at 48, 72 and 96h p.i. Similar differences were also observed for NS4-IIα and 
IIγ and the corresponding ∆NS4-II viruses (Figure 5.1B).In stark contrast, the 
replication kinetics of the reassortant expressing NS4-IIβ and the corresponding ΔNS4 
mutant did not show any difference. Our results indicate AHSV NS4-I, NS4-IIα and IIγ 
provide a replication advantage to AHSV in equine cells. 
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Figure 5.1 Virus growth kinetics in Kc cells (A) and E. Derm (B) cells. Cells were infected at a 
MOI ~0.01 and cell-free virus was harvested at the time points indicated. Titres were determined 
by limiting dilution and expressed as TCID50/ml. In KC cells, the growth kinetics of all the ΔNS4 
viruses (blue) were similar to that of related wt viruses (red). In contrast, in E. Derm cells, wt 
viruses grew to higher titres than NS4 deleted viruses, except for NS4-IIβ wt and mutant viruses. 
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Each experiment was performed three times independently using two independently generated 
virus stocks. 
 
5.2.3 Type I IFN hampers AHSV replication  
Next, we investigated whether NS4 could facilitate AHSV replication in cells in which 
an antiviral state was induced by pre-treatment with IFN. 
E. Derm cells treated with 1000U of uIFN for 24 h or mock-treated were infected 
with AHSV-4, AHSV segment 9 reassortants and NS4 deletion mutants as per previous 
experiments and supernatants titrated in BSRC cells at different time points p.i. As 
expected, titers of all viruses used in the experiment were lower at all time points 
in cells pre-treated with IFN (Figure 5.2). For example the titres of the AHSV NS4-I 
wt and ΔNS4 viruses decreased ~1log10 at 24 h p.i. and over ~2log10 at 48 h p.i in IFN-
treated cells compared to the mock-treated controls. Hence, the presence or 
absence of NS4 did not affect the sensitivity of AHSV to IFN. Similar results were 
obtained for viruses expressing NS4-IIα, β and γ and the corresponding NS4 deletion 
mutants; replication of both sets viruses was restricted in cells were pre-treated 
with IFN (Figure 5.2). The titres reached by AHSV NS4-I, -IIα and –IIβ in IFN-treated 
E. Derm cells was about 100 fold lower at 48 h p.i than the titers reached in mock-
treated cells. Treatment with IFN reduced the titers reached by AHSV NS4-IIγ, only 
about 10 folds (Figure 5.2). 
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Figure 5.2 Virus growth kinetics of wt (red) and NS4 (blue) viruses in E. Derm cells pre-treated 
with IFN. Cells were pre-treated with 1,000 u of uIFN and infected with a MOI~0.01. Cell-free virus 
was harvested at the time points indicated and titres were determined by limiting dilution and 
expressed as TCID50/ml. The dashed lines indicate virus samples harvested from IFN pre-treated 
cells. IFN pre-treatment significantly decreased the titres of both wt and ΔNS4 viruses at all 
times points analysed (p<0.0001). Each experiment was performed three times independently 
using two independently generated virus stocks. 
 
5.2.4 NS4 confers a replicative advantage to AHSV in equine primary cells. 
E. Derm is an immortalised cell line. The cells appear to be relatively unstable and 
their chromosome numbers for example varies widely between 52 and 145 (whereas 
the horse genome contained 64 chromosomes) (ATCC). Hence, various pathways in 
E. Derm, including IFN induction and response may vary widely in these cells 
between different passages. Indeed we observed inconsistent data when we 
attempted to measure IFN induction in E. Derm as a result of AHSV infection. 
Therefore, we generated primary endothelial cells from horse aorta to further 
investigate the function of the AHSV NS4. As expected, these cells were able to 
produce IFN in response to polyI:C stimulation (data not shown). The viral replication 
kinetics of the different viruses used in this study in primary horse endothelial cells 
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was similar to those observed in E. Derm cells. The titers reached by AHSV NS4-I, IIα 
and -IIγ in primary horse endothelial cells were at least 10 times higher than the 
corresponding ΔNS4 viruses (Figure 5.3). On the other hand, the replication kinetics 
of AHSV NS4-IIβ and the corresponding ∆NS4 mutant were essentially identical in 
these cells (Figure 5.3). 
 
Figure 5.3 Replication kinetics of wt (red) and NS4 (blue) viruses in horse primary aorta 
endothelial cells. Cells were infected with a MOI~0.1. Cell-free virus was harvested at the time 
points indicated and titres were determined by limiting dilution and expressed as TCID50/ml. 
AHSV wt expressing either NS4-I, NS4-II or  generated higher virus titres at each time point in 
comparison to the respective ΔNS4 viruses. NS4-IIβ wt and mutant viruses were an exception 
with similar titres observed at all time points. Each experiment was performed three times 
independently using two independently generated virus stocks. 
 
5.2.5 Inhibition of the IFN response rescues the replication defect displayed by 
AHSV NS4 deletion mutants in primary horse cells. 
Collectively, the data presented in section 5.2.3 and 5.2.4 suggested that NS4 
favours virus replication in IFN competent cells. Hence, we repeated the growth 
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curve assays described above in cells treated (or mock-treated) with ruxolitinib, in 
order to rule out that factors other than IFN affect the replication of the AHSV NS4 
deletion mutants. Ruxolitinib is an inhibitor of the JAK/STAT pathway, hence cells 
treated with this chemical are unable to mount an effective IFN response (Delgado-
Martin, Meyer et al. 2017). Horse aorta endothelial primary cells were treated with 
5μM ruxolitinib for 4 h, and then infected with the different AHSV recombinant 
viruses used above or the corresponding ΔNS4 viruses. Supernatants were collected 
at 24, 48, 72 and 96 h.p.i and then titrated in BSR cells. In cells treated with 
ruxolitinib the NS4 deletion mutants in general replicated as efficiently as the 
viruses possessing the NS4. Treatment with ruxolitinib increased the replication 
efficiency of both viruses with and without NS4 (Figure 5.4). This is in contrast to 
the mock-treated horse aorta endothelial primary cells where viruses expressing 
NS4-I, IIα and IIγ reached higher titres than the corresponding NS4 deletion mutants. 
Interestingly, we observed that AHSVΔNS4-IIβ reached higher titres than AHSV-NS4-
IIβ virus in ruxolitinib treated cells (Figure 5.4). This is in contrast to the untreated 
cells where the replication kinetics of these two viruses was essentially the same. 
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Figure 5.4 Viral replication kinetics in horse primary cells pre-treated with ruxolitinib. Horse 
aorta endothelial cells were pre-treated with 5 μM ruxolitinib and infected at a MOI 0.1. Cell-free 
virus was harvested at the time points indicated and titres were determined by limiting dilution 
and expressed as TCID50/ml. Viruses titres from ruxolitinib-treated cells are depicted as dashed 
lines while titres from untreated cells are depicted by solid lines. Wild-type viruses are depicted 
in red and NS4 viruses in blue. A. The average and standard deviations of 3 independent 
experiments is presented. Both wt and DNS4 viruses grew to similar titres. However, the titres 
in ruxolitinib-treated cells were higher than in untreated cells at time points. (B) Given that 
primary cells are intrinsically variable, the data from each of the 3 independent experiments is 
also shown. 
These results indicated that at least NS4-I, IIα and IIγ have a role in modulating the 
IFN response during AHSV infection. 
5.2.6 The AHSV NS4 hampers IFN induction in infected horse cells 
Next, we carried out an IFN protection assay in order to further understand the role 
of AHSV NS4 in modulating the host antiviral responses. Primary horse aorta 
endothelial cells were infected at high MOI and cell supernatants were harvested to 
measure the IFN response as described in Materials and Methods. 
Initially, it was important to find the best method to quantify type-I IFN production 
in horse cells. We acquired a commercial ELISA kit (The Equine IFNβ Do-It-Yourself 
Kit; Kingfisher Biotech Inc) but we were not able to detect IFN produced by horse 
cells infected by Sendai virus (rich in defective interfering particles; a gift from Prof. 
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Rick Randall), although the kit was able to detect recombinant equine IFNβ up to a 
concentration of 12.44ng/ml IC50. Hence, we used a biological assay where the 
detection of IFN in AHSV infected cells is based on the inhibition of an IFN sensitive 
virus (encephalo myocarditis virus, EMCV) in target cells. In order to select the 
indicator cell line, a variety of cell lines were treated with commercial equine IFNα1 
(eIFNα1) and then infected with EMCV. The results confirmed the findings of (Adolf, 
Traxler et al. 1990) that neither A549 nor A549-Npro responded to eIFN (DATA NOT 
SHOWN). On the contrary CPT-Tert cells (an immortalised sheep choroid plexus cell 
line) were sensitive to and established an antiviral state after treatment with eIFN 
(Figure 5.5). CPT Tert cells were completely protected when cells were treated with 
as little as 25 pg/ml of eIFNα1; while 50% of the monolayer was protected when cells 
were treated with 12.5 pg/ml of eIFNα1. As expected, supernatants from mock-
infected cells did not protect CPT-Tert cells against EMCV-induced CPE, suggesting 
that there was no background IFN secreted from uninfected primary horse cells 
(Figure 5.5A). Hence, CPT-Tert cells were used as indicator cell line. 
Horse primary endothelial cells were infected with the full set of AHSV viruses 
expressing the different forms of the NS4 protein and the corresponding ΔNS4 viruses 
(at ~MOI 2). Supernatant was collected at 24 h p.i, UV-treated (to inactivate AHSV) 
and added to CPT-Tert cells for 24h. Subsequently, media was removed and cells 
were challenged with EMCV for 48 h before staining with crystal violet in order to 
assess cytopathic effect. Serial dilutions of eIFNα1 were used as positive control and 
to calibrate the results obtained with the supernatants of AHSV infected cells. 
Consistently, we observed that primary aorta endothelial cells produced higher 
levels of IFN when infected with the ΔNS4 rescued viruses compared to the 
corresponding viruses expressing NS4 (Figure 5.5A). These results suggest that the 
AHSV NS4 play a role in modulating the IFN response. 
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Figure 5.5 Production of IFN in horse endothelial cells in response to infection of AHSV wt and 
ΔNS4 virus. Horse aorta endothelial primary cells were infected with AHSV wt or ΔNS4 viruses 
at MOI~2. Supernatants were harvested 24 h post infection and UV-treated to deactivate AHSV. 
The medium was serially diluted and placed onto CPT-Tert cells. CPT-Tert cells were challenged 
24 h later with ECMV for 48 h, fixed and stained with crystal violet. Equine IFNα1 (eIFNα1) was 
used as a positive control and calibrator. Supernatants were 2-fold serially diluted from the top 
lane to bottom lane. A. Crystal violet-stained CPT-Tert cells from a representative experiment. 
B. Equivalent IFN concentration in supernatants infected with the indicated viruses from 3 
independent experiments performed in duplicate. Note that differences between the equivalent 
amounts of IFN released in the supernatants of the viruses expressing NS4 and the 
corresponding NS4 viruses were the following: p=0.2891 (NS4-I vs NS4-I); p= 0.0161 (NS4-II 
vs NS4-II); p=0.0056 (NS4-II vs NS4-II); p=0.068 (NS4-II vs NS4-II). The lack of statistical 
support in two of the series can be explained by two factors. The first one is that in one of the 
experiments we obtained higher levels of IFN released by cells infected with NS4-I and NS4-
IISecondly, and more importantly, samples were not diluted enough to calculate accurately 
the amount of IFN released by NS4 cells. This means that the amount of IFN released by cells 
infected with the NS4 viruses is likely higher than what has been calculated 
AHSV expressing NS4-IIβ appeared to be the most efficient in counteracting the IFN 
response of the cell in comparison to the viruses expressing the other types of NS4. 
AHSV NS4-I, NS4-IIα and γ were able to suppress the production of IFN in comparison 
to their respective mutants to varying degrees (Figure 5.5). NS4-IIa was the next 
most efficient at reducing IFN production with ~133 pg/ml, followed by NS4-I and 
NS4-IIg that both had an average of 300 pg/ml (Figure 5.5B). There was quite large 
variation in the amount of IFN secreted in to the cell culture supernatants by these 
viruses and this may be due to the different batches of primary cells used in these 
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experiments (see appendix II). Despite these batches difference, there was a 
difference in the ability of the AHSV viruses expressing NS4 to decrease IFN 
production in comparison to the ΔNS4 viruses (Figure 5.5B). These results confirmed 
our hypothesis that NS4 has role in limiting the IFN response to infection. 
5.2.7 AHSV NS4 is a determinant of virus virulence in experimentally infected mice 
 Next, we investigated whether NS4 could be identified as a determinant of virus 
virulence in vivo in experimentally infected mice. NIH Swiss new-born mice were 
inoculated intracerebrally with 200 pfu of AHSV expressing the different types of 
NS4 or the corresponding deletion mutants (1 litter for each virus) (animal 
inoculations and monitoring were carried out by Marco Caporale at the IZS Teramo, 
Italy). Each of the viruses used killed 100% of the infected animals. However, all 
animals inoculated with ΔNS4 viruses survived longer than those infected with 
viruses expressing NS4 (NS4-I, p=0.0048; NS4-IIα, p<0.0001; NS4-IIβ, p<0.0001; NS4-
IIγ, p=0.0002) (Figure 5.6). Indeed 50% of the mice inoculated with NS4 expressing 
viruses died by day 4 p.i. and 100% by day 6 p.i. (Figure 5.6). Conversely, mice 
inoculated with the ΔNS4 viruses did not start dying until day 5 and all (but one) 
died by day 8. These results therefore suggest that NS4 is a determinant of viral 
pathogenesis. 
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Figure 5.6 AHSV NS4 is a determinant of virulence. Kaplan-Meier plots displaying survival of 
new-born NIH-Swiss mice inoculated intracranially with 200 PFU of the indicated viruses. 
Survival rate was monitored for 14 days.  
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5.3 Discussion 
In this chapter we aimed to understand the biological function of the AHSV NS4. 
Previous studies on the phylogenetically related BTV have found that its NS4 protein 
is an IFN antagonist (Ratinier, Caporale et al. 2011, Ratinier, Shaw et al. 2016). 
Hence, in this Chapter we concentrated our efforts on determining whether also the 
AHSV NS4 modulates the antiviral response of the host. Experiments in this thesis 
showed that the NS4 does not provide any replication advantage to AHSV in the IFN-
incompetent BSR cells or in the culicoides Kc cells. These results suggest that NS4 
does not play any major role in virus replication per se. 
However, AHSV NS deletion mutants (with the exception of AHSV-NS4II-β) replicated 
less efficiently than the corresponding viruses expressing NS4 in IFN competent cells 
(E. Derm cells and horse primary endothelial cells). Importantly, the AHSV∆NS4 
mutants replicated as efficiently as the corresponding NS4 expressing viruses when 
the same cells were treated with an inhibitor of the JAK/STAT pathway, and 
therefore inhibiting the IFN response. Furthermore, by IFN protection assays we 
established that high levels of IFN were detected in the supernatants of primary 
horse cells infected with the ΔNS4 viruses but not with the corresponding “wild type” 
viruses expressing NS4  
Hence, the NS4 is at least one of the tools used by AHSV to modulate the IFN 
response. In vivo, we found the AHSV NS4 is a determinant of virulence at least in 
an experimental mouse model of AHS. Interestingly, the NS4 did not provide a 
replication advantage in cells which were already in an antiviral state as a result of 
IFN stimulation. Collectively, the data obtained suggest therefore that the AHSV NS4 
blocks IFN induction. 
We obtained seemingly contradictory results with AHSV-NS4II-β. Similarly to the 
other three types of NS4, NS4II-β was also proven to modulate the IFN response in 
vitro and be a determinant of virulence in vivo. However, AHSV-∆NS4II replicated as 
efficiently as AHSV-NS4II in both E. Derm and primary horse endothelial cells. Hence, 
NSII behaves as an IFN antagonist but does not provide a replication advantage to 
AHSV in IFN competent cells. Interestingly, in ruxolitinib-treated cells, AHSV∆NS4IIβ 
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replicated even more efficiently than AHSV-NS4IIβ. It appears therefore that NS4IIβ 
has additional features that distinguish it from the other types of AHSV NS4 and more 
studies will be required to understand these differences.  
The results obtained in this chapter demonstrate that both the orbiviruses BTV and 
AHSV utilise their NS4 proteins to modulate the antiviral responses of the host. 
However, it is interesting to note that there are important differences in the 
mechanisms followed by these two proteins to modulate the IFN response of the 
host. First of all, the BTV NS4 has a strong nucleolar localisation as opposed to the 
cytoplasmic localisation of the AHSV NS4 (Ratinier, Caporale et al. 2011). In addition, 
the BTV NS4 is able to provide a replication advantage to BTV in cells already in an 
antiviral state as a result of IFN pre-treatment. The BTV NS4 has been suggested to 
act at the level of cellular transcription. The AHSV NS4 seems to act before the 
transcription of IFN, hence at either PAMP detection, downstream signalling or 
transcription. More studies will be necessary to dissect how exactly the AHSV NS4 
inhibits the IFN response. 
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 General Discussion 
The major objective of this project was to investigate the functions of AHSV NS4 in 
viral infection and replication in mammalian cells, and to investigate if this protein 
played any roles in counteracting the host IFN response. The origins of this project 
were inspired by the detection of an overlapping ORF in orbivirus segment 9 (Firth 
2008), including BTV, AHSV, PALV and PHSV/YUOV and the role that BTV NS4 has in 
subverting the IFN response (Ratinier, Caporale et al. 2011, Ratinier, Shaw et al. 
2016). During this research project, research published by others including the 
development of a RG system for AHSV (Kaname, Celma et al. 2013) (Van de Water, 
van Gennip et al. 2015) (Conradie, Stassen et al. 2016) and the identification of 
AHSV NS4 in infected cells were reported (Zwart, Potgieter et al. 2015). Although 
these papers were published, a question remained to be answered: what is the role 
of AHSV NS4 during virus replication? 
The bioinformatics analysis presented in this thesis supported the finding of Zwart 
et al. and not Firth confirming that there were at least two forms of NS4 (NS4-I and 
NS4-II). NS4-I and NS4-II share between 45.6% to 59.5% similarity and cluster into 
two phylogenetically distinct clades. Segment 9 VP6 and NS4 ORFs are not the only 
AHSV segments that cluster into distinct clades with high variation observed at the 
amino acid level. Segment 10 clusters into 3 clades (Quan, Van Vuuren et al. 2008) 
(Martin, Meyer et al. 1998) (Van Niekerk, Freeman et al. 2003) and Segment 1 into 
two distinct clades (see Chapter 3 Figure 3.3). Our analysis of NS4, VP1 and VP3 
supported that the segment reassortment of AHSV genome was not linked to virus 
serotypes and that there appeared to be no obvious factors influencing genome 
reassortment. In the field, reassortment appears to be associated with increased 
viral fitness with virus derived from the live attenuated vaccine strains associated 
with virulent outbreaks (Weyer, Grewar et al. 2016). Traditionally virulence has 
been associated with reassortment of segments 2 and 5 and 10 (Quan, Van Vuuren 
et al. 2008). Weyer et al. suggested that along with VP2 and VP5, VP6 also has a role 
in virulence (Weyer, Grewar et al. 2016). We did not have any of these changes in 
the VP6 sequences used in our backbone viruses, indicating that the differences in 
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virulence and replication observed between the rescued viruses are most likely due 
to NS4. 
Moreover, here we showed that there are three different forms of NS4-II, which we 
refer to as NS4-IIα, β and γ based on N- and C-terminal truncations, which had not 
been identified by either Firth or Zwart et al (Firth 2008) (Zwart, Potgieter et al. 
2015). We identified other smaller truncated forms but these all derived from highly 
passaged cell culture adapted-viruses and we hypothesized that these forms of NS4 
do not exist in the field. The different forms of AHSV NS4: NS4-I, NS4-IIα, β and γ, 
comprised 26.1%, 4.3%, 67.9% and 1.7% respectively of the circulating field strains 
with the NS4-II forms being the most common. 
When comparing the percentage of NS4 populations in the field isolates with the 
prevalence of the different forms of disease, one could speculate that the 
percentages of different disease outcomes is roughly similar. Among the four 
presentations of AHS, the mixed form is the most common form whereas the horse 
sickness fever is the least. Thus, we propose a very bold hypothesis that the four 
types of NS4 are associated with the different clinical presentations of AHS. Until 
data linking disease outcome to sequence information of whole isolates is available 
this will not be validated. Although, we inoculated IFN competent mice with the RG 
engineered-viruses expressing the different NS4 proteins, there were no statistical 
significant differences in the survival rates among the different groups. Mice may 
not be the best model to study AHSV pathogenesis and this type of studies may be 
better suited for ponies or horses. 
In order to investigate the role of AHSV NS4, comparative analysis was made with 
BTV NS4 due to the position and conservation in the genome. Although AHSV NS4 is 
almost twice the size of BTV NS4 (143 to 169 aa compared to 77 to 79 aa) and AHSV 
NS4 has more than one form, there are similarities. The BTV NS4 C-terminal part 
contains a conserved sequence where leucine residues are present at positions 49, 
56, 63 and 70 (Ratinier, Caporale et al. 2011). In this study, I identified a putative 
leucine zipper in the AHSV NS4 consensus sequence (NS4-I and NS4-II see chapter 3 
Figure 3.2) with leucine residues spaced every 7–8 residues (aa positions 92, 100, 
108 and 115). This is a typical feature of leucine zipper domains (that leucine residue 
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occurs every 7 aa). Functionally leucine zipper domains have a role in binding protein 
to DNA, but would not preclude the proteins ability to bind ssRNA and/or dsRNA. 
The DNA binding function of AHSV was eluded by Zwart et al (Zwart, Potgieter et al. 
2015), who undertook a DNAse and RNAse protection assay. However, this property 
for NS4 needs to be further validated through either mutational studies, 
electrophoretic mobility shift assay (EMSA) and sequence analysis of the fragments 
of nucleic acid the protein is interacting with to determine if it is a specific effect. 
Although, there is this putative leucine zipper and data suggesting DNA binding 
ability, the localisation studies of NS4 presented here revealed that all forms of the 
proteins did not localise in cell nucleus but were diffuse throughout the cytoplasm 
(Chapter 3 Figure 3.6, Figure 3.7). There was no specific localisation to any of the 
cellular structures or organelles. This contrasts with BTV NS4, which localises to the 
nucleolus and the data presented by Zwart et al (Zwart, Potgieter et al. 2015) that 
indicated that AHSV NS4 localises to both the nucleus and the cytoplasm. The diffuse 
localisation of the proteins did not provide insights or direction to follow up the 
functional analysis. 
In order to control the host cell response against viral infection, virus including BTV 
(Ratinier, Shaw et al. 2016) and Schmallenberg virus (SBV), (Varela, Pinto et al. 
2016) have been known to shutdown the host protein synthesis. For SBV, this 
function was attributed to the non-structural protein NSs and the glycoprotein (Gc). 
For BTV, 3 non-structural proteins have been implicated including NS3, S10-ORF2 
and NS4 (Chauveau, Doceul et al. 2013) (Ratinier, Shaw et al. 2016) (Stewart, Hardy 
et al. 2015) (Varela, Pinto et al. 2016). Therefore, the role of AHSV NS4 in host 
protein shutdown was assessed using a firefly luciferase expression assay. The data 
revealed that all the forms of NS4 could decrease firefly expression but there were 
differences the degrees that Firefly luciferase expression was turned off. NS4-IIβ had 
the strongest effect on firefly luciferase expression (~77% decrease) while NS4-IIγ 
was the weakest (~10%). NS4-I and NS4-IIα acted similarly with 25% decrease in 
activity in comparison to the control. A major difference was associated with 
truncation in the NS4-IIβ and IIγ in comparison to the full length of NS4-IIα and NS4-
I. The removal of either the N-terminal from NS4-IIβ or the C-terminal from NS4-IIγ 
changed the ability of the proteins to affect host cell protein synthesis (NS4-IIβ 75% 
 133 
 
decrease and NS4-IIγ 10%). This data would indicate that the ability to shutdown was 
in the core region of the protein and the N- and C-terminals suppress or enhance 
this ability, respectively. Other form of AHSV NS4s, NS4-IIγ lacks 26 aa at C-terminal, 
therefore the C-terminal of AHSV NS4 should play the critical role in host protein 
shutdown. Although the experiments were not undertaken here, to further validate 
this hypothesis, the NS4-IIα sequence should be truncated at the N- and C-terminal 
to generate either NSI-IIβ or γ and the assay repeated to examine whether the 
phenotypes could be recapitulated.  
Studying a protein outside of the context of virus replication only provides limited 
information and overstates or understates the role of the protein. In order to 
investigate the role of NS4 in virus replication, a reverse RG had to be established. 
During the time that the RG was developed in the laboratory, three research groups 
published an AHSV RG system (Kaname, Celma et al. 2013, Van de Water, van Gennip 
et al. 2015, Conradie, Stassen et al. 2016). The RG system developed in this thesis 
was similar to Kaname and Van de Water using a two-step transfection protocol 
(Kaname, Celma et al. 2013, Van de Water, van Gennip et al. 2015). This enable the 
successful rescue of AHSV wt and ΔNS4 viruses for the four forms of NS4 and provided 
opportunities to investigate the functions of this protein during virus replication. 
Similar to BTV NS4 and AHSV NS3 and VP2, AHSV NS4 was not required for the 
successful rescue of the reassortant viruses and that its function like other non-
structural and accessory proteins maybe cell type dependent. 
This assumption was inferred by the replication kinetics data of both AHSV wt and 
ΔNS4 viruses in an interferon-incompetent mammalian cell line (BSR) and in an insect 
cell line (Kc) where no significant or observable differences were found at any of 
the time points investigated. The size and shape of plaques in BSR cells did not 
display any difference and the dsRNA genome was not affected by lack of NS4 
expression. This ruled out the role of AHSV NS4 in the dsRNA genome synthesis, virus 
assembly, egress of the particle and cell-to-cell spread to the virus. 
As BTV NS4 had a similar phenotype in both BSR (interferon incompetent) and the 
vector host cell line, it was a natural progression to investigate if AHSV had a role in 
antagonising the IFN response. To date the IFN response to AHSV has not be studied 
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unlike BTV where there were studies in 1969 measuring the production of IFN in vitro 
and in vivo in response to infection (Huismans 1969) and the role of the cytokine 
storm and IFN in controlling infection (DeMaula, Jutila et al. 2001, DeMaula, 
Leutenegger et al. 2002) (Ratinier, Shaw et al. 2016).There has only been one study 
(de la Grandière, Dal Pozzo et al. 2014) that has eluded to the role that IFN plays in 
controlling the infection in IFN-competent mice in comparison to IFNAR(-/-) mice. In 
this study, we have reported that IFN influences AHSV replication and that AHSV NS4 
acts as an antagonist of IFN induction. The replication kinetics of AHSV wt viruses in 
an equine-derived cell line (E. Derm cells and horse primary endothelial cells) was 
significantly higher than that of the corresponding ΔNS4 viruses except for NS4-IIβ. 
Regardless of whether NS4-IIβ was present or not, there was no difference in the 
replication kinetics of the virus. 
The role of AHSV NS4-I, NS4-IIα -IIβ and -IIγ as IFN antagonists was further supported 
when the JAK/STAT pathway was blocked by ruxolitinib, which stops the induction 
of IFN. The viral titres at all time points for the AHSV ΔNS4 viruses increased, 
including AHSV NS4-IIβ ΔNS4 virus. When ruxolitinib was added to the cells, the ΔNS4-
IIβ virus grew to higher titres than wt virus, which was unexpected. It could be 
speculated from these results that NS4-IIb is an IFN antagonist but its ability to 
shutdown host cell proteins to the extent that it does has a detrimental effect on 
the viruses i.e., it comes at the expense of virus fitness. Pre-treatment of E. Derm 
cells with IFN caused a similar restriction on both the wt and ΔNS4 viruses growth. 
We expected that the growth of the ΔNS4 viruses would have been more retarded 
than the wt, but as E. Derm cells respond to and secret IFN this may have confounded 
the experiment. It would be important to use a cell line that responds to IFN to 
induce an antiviral state but does not have the capacity to produce IFN or keep IFN 
in the media to study these phenomena in greater depth. 
To monitor the effect of IFN production in response to AHSV, we set up a biological 
assay that enables equine IFN to be measured; this was the first time such a study 
has been performed. Infection of horse primary endothelial cells with AHSV 
regardless of which type of NS4 was expressed, did not induce the release of very 
much IFN into the supernatant. This was particularly obvious in the supernatant of 
AHSV NS4-IIβ wt-infected cells, with the IFN concentration below the detectable 
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limits of the assay. In contrast, high concentrations of IFN were secreted in the 
supernatant from cells infected with AHSV ΔNS4 viruses, including ΔNS4-IIβ. This 
data supported of the assumption that NS4 acts as an antagonist of IFN. 
It was not surprising that AHSV infection stimulated an IFN response and encodes a 
potential IFN antagonist. Like BTV, the AHSV genome dsRNA is also a strong PAMP 
for host cell IFN response and the outer capsid proteins have been shown to induce 
apoptosis (Mortola, Noad et al. 2004, Stassen, Huismans et al. 2012, Vermaak and 
Theron 2015). Host cell sensors, including RIG-I and MDA5 are upregulated and 
activated in response to AHSV. The activation of sensors results in the production 
and secretion of IFN. Viral non-structural proteins play a role in counteracting host 
interferon response in diverse ways. For example, the Influenza A viral protein NS1 
prevents RIG-I to recognise viral genome as PAMP (Guo, Chen et al. 2007) and the 
NSs protein of Schmallenberg virus inhibits the host cell transcriptional machinery 
to block the IFN response (Barry, Varela et al. 2014). As AHSV NS4 shuts down the 
host cell protein synthesis, with NS4-IIβ being the most efficient one, it is 
hypothesised that AHSV NS4 may regulate host cell translation. Furthermore, the 
arginine rich motif (RXRRQRL) identified in this study in the C-terminal of AHSV NS4 
may play a role in host cell mRNA binding in order to block the translation. However, 
this needs to be verified using mutational and ssRNA:protein interaction studies. 
We had postulated that not only was AHSV NS4 a potential IFN antagonist but also 
may have a role in virulence based on the NS4 variability and disease prevalence 
(i.e. NS4-IIβ was the most frequent and the mixed form of disease is the most 
common presentation). Therefore, we tested the virulence of the viruses in IFN 
competent 4-day-old NIH-Swiss new-born mice. The wt viruses were all more virulent 
that the NS4-deletion viruses but were not significantly different to each other. 
Furthermore, the lack of NS4 did not prevent death, but significantly increased the 
time of survival compared to animals infected with wt AHS. Although, this would 
suggest that AHSV NS4 plays roles in blocking the host innate immune system and a 
determinant of virulence, it would be critical to find a better model to examine 
virulence such as the horse. 
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6.1 Future work 
There were drawbacks in this project. In order to study NS4-IIα, β and γ, the AHSV-
4 genome was reassorted with the whole segment 9 from AHSV-7, -1 and -6 to 
generate the AHSV NS4-IIα, β and γ respectively. However, this resulted in the 
expression of different VP6 proteins, although the amino acid sequences were 
similar, they were not the same, which may also impact on the viral replication. VP6 
has been implicated in virulence but the amino acid residues responsible for this are 
not in the sequences used in the viruses rescued here. Thus, for the future work to 
study the potential functions of the C-terminal and N-terminal regions of AHSV NS4-
II, it is important to introduce the mutations on the same sequences. 
To further analyse the role of AHSV NS4 interacting with the host interferon 
response, a protein-protein interaction assay is needed to reveal the binding target 
either protein in the IFN induction pathway or specific ISG or the functional site of 
AHSV NS4 in counteracting the IFN pathway. This could be performed using an over 
expression assay linked to a firefly reporter assay and co-immunoprecipitation such 
as the one used for Ukanemi virus (Rezelj, Li et al. 2017). 
AHSV NS4 nucleic acid binding activity has been shown (Zwart, Potgieter et al. 2015), 
however the data needs further validation. As a putative leucine zipper domain and 
a putative arginine-rich domain have been identified in this work further mutational 
and nucleic acid:protein interaction studies are required. 
It would be also interesting to explore the global effect of AHSV NS4 manipulation 
of host transcription and/or translation. This could be achieved by using RNA-seq 
technique as described for BTV (Ratinier, Shaw et al. 2016). It would be important 
to undertake this study in primary horse cells that are IFN competent rather than a 
cell line like A549 (AHSV cannot replicate in these cells). This would allow us to 
compare the upregulation of ISGs mRNA levels of wt and ΔNS4 virus-infected cells 
and could define the key genes of the host innate system in response to AHSV 
infection. 
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6.2 Concluding statement 
This study provides an overview of the role of the NS4 protein. NS4 has a clear role 
in antagonising the IFN response and the mice studies highlight that it may have a 
role in the virulence in vivo. Indeed, it is easy to speculate that this protein maybe 
a diagnostic indicator of the clinical outcome of disease. However, the details of the 
exact function and mechanisms of action of the protein in the context of viral 
replication are unclear and it would be important to undertake follow up studies to 
investigate this, particularly for NS4-II which is functionally different. 
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Appendix I 
standard solution 
Phosphate buffered saline (PBS) 10 mM Na2HPO4 
150 mM NaCl  
pH 7.4 
 
Luria Bertani (LB) Medium  1% (w/v) Bacto-tryptone 
     0.5% (w/v) Yeast extract 
     0.5% (w/v) NaCl  
     in deionized water 
 
LB plates    LB Medium 
     1.5 % (w/v) agar 
 
PBS-tween    10 mM Na2HPO4 
150 mM NaCl  
0.1% (v/v) Tween-20 
pH 7.4 
 
6× DNA/dsRNA loading dye 10 mM Tris-HCl 
     60 mM EDTA 
     0.03% (w/v) bromophenol blue 
     60% (v/v) glycerol 
 
4× protein loading dye  200 mM Tris-HCl (pH 6.8) 
     30% (v/v) glycerol 
     10% (v/v) β-mercaptoethanol 
     0.03% (w/v) bromophenol blue 
     8% (w/v) sodium dodecyl sulfate 
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Tris-acetate-EDTA buffer  40 mM Tris 
     20 mM acetic acid 
     1 mM EDTA      
     pH 8.0 
 
Tris-Glycine transfer buffer 120 mM glycine     
     25 mM Tris      
     20% (v/v) methanol     
     pH 8.3 
4% formaldehyde   4% in PBS, pH 7.4-8.0 
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Appendix II 
 
Production of IFN in horse endothelial cells in response to infection of AHSV wt and ΔNS4 virus. 
Horse aorta endothelial primary cells were infected with AHSV wt or ΔNS4 viruses at MOI~2. 
Supernatants were harvested 24 h post infection and UV-treated to deactivate AHSV. The 
medium was serially diluted and placed onto CPT-Tert cells. CPT-Tert cells were challenged 24 
h later with ECMV for 48 h, fixed and stained with crystal violet. Equine IFNα1 (eIFNα1) was used 
as a positive control and calibrator. Supernatants were 2-fold serially diluted from the top lane 
to bottom lane. The experiment has been carried out by triplicate due to the different batches of 
primary cells used in these experiments. A. The second repeat of the experiment. Horse 
endothelial cells interferon production was inhibited when infected with AHSV wt type compared 
with the corresponding ΔNS4 viruses. B. The third repeat of the experiment. AHSV NS4-IIβ 
inhibited the primary cells interferon production completely, while AHSV NS4-IIα slightly 
inhibited the production. However, we did not identify the difference of the capability of host cell 
inhibition between AHSV NS4-I, ANSV NS4-IIγ and the corresponding ΔNS4 viruses in this 
experiment. 
 
 
